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5.1 Pancreatic cancer 
Pancreatic cancer is one of the most aggressive human malignancies due to its late 
diagnosis and limited response to treatments. The most common malignancy of the 
pancreas, accounting for almost 80% of the pancreatic cancer incidences (Kleeff et al. 
2016), is pancreatic ductal adenocarcinoma (PDA). In 2018, 458.000 new pancreatic 
cancer cases were estimated worldwide with a high death toll of 432.000 (Bray et al. 
2018). In the United States the year 2019, pancreatic cancer is expected to remain the 
fourth leading cause of cancer-related death, with a very low 5-year survival rate of 9% 
(Siegel et al. 2019). In order to manage this deadly cancer, understanding of the 
molecular mechanisms of pancreatic tumor progression as well as development of new 
therapeutic strategies are urgently needed. 
 
5.1.1 Pathophysiology, risk factors and staging 
Pancreatic cancer mainly originates from ductal epithelial cells and evolves from pre-
malignant lesions such as intraductal papillary mucinous neoplasms (IPMN), mucinous 
cystic neoplasms and the most histologically characterized precursor lesion called 
pancreatic intraepithelial neoplasia (PanIN) (Iacobuzio-Donahue et al. 2012). PanIN 
microscopic lesions progress from low to high dysplasia in three different grades, PanIN-
1, PanIN-2, and PanIN-3 (Hruban et al. 2001) (Figure 1). The transformation is a result 
of the accumulation of genetic mutations that include inactivation of the KRAS and 
CDKN2A (in almost 95% of pancreatic cancer cases) or activation of the TP53 and 
SMAD4 (in 75% and 55% of pancreatic cancer cases, respectively) (Hidalgo 2010). The 
causes of the accumulation of these mutations leading to invasive pancreatic cancer are 
largely unknown, however there are some important risk factors including smoking, 
heavy alcohol consumption, obesity, chronic pancreatitis, type 2 diabetes mellitus and 









                       KRAS      CDKN2A    TP53   SMAD4  
Figure 1. Progression of pancreatic cancer lesions in humans. Schematic representation of normal 
exocrine pancreas cells transforming from PanIN (left) to invasive tumor (right) (Modified from 
(Iacobuzio-Donahue et al. 2012)).  
 
The majority of malignant neoplasms in the pancreas in terms of percentage of incidence 
include adenocarcinomas, followed by neuroendocrine tumors, solid-pseudopapillary 
tumors and acinar cell carcinomas (Kleeff et al. 2016). After the diagnosis of pancreatic 
cancer, the next step in order to define the treatment is the staging. Tumor-node-
metastasis (TNM) classification of pancreatic cancer is widely established by the 
American Joint Committee on Cancer (AJCC) (Table 1). The information that is taken 
into account to define the stage includes the location and size of tumor, the association 
of lymph nodes and distant metastasis (Longo 2012). Patients with advanced stages III 
and IV cannot undergo putative curative surgery and the median survival time for these 
patients ranges between 4 and 6 months.  
 
Table 1: AJCC staging for pancreatic cancer 
AJCC stage 
Anatomic stage Characteristics 
T N M 
Stage IA T1 N0 M0 
Tumor limited to pancreas 
Stage IB T2 N0 M0 
Tumor limited to pancreas 
Stage IIA T3 N0 M0 
Tumor beyond pancreas without lymph-
node metastasis 
Stage IIB 
T1 N1 M0 Tumor beyond pancreas with 
Regional lymph-node metastasis T2 N1 M0 
T3 N1 M0 
Stage III T4 Any N M0 
Tumor involved celiac axis or superior 
mesenteric artery 




Primary Tumor (T); T1: Tumor 2 cm or less in greatest dimension; T2: Tumor more than 2 cm in greatest 
dimension; T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the 
superior mesenteric artery; T4: Tumor involves the celiac axis or the superior mesenteric artery; Regional 
Lymph Nodes (N); N0: No regional lymph node metastasis; N1: Regional lymph node metastasis; 
Distant Metastasis (M); M0: No distant metastasis; M1: Distant metastasis (Adapted from (Hidalgo 
2010)).  
 
5.1.2 Current therapeutic options 
Pancreatic cancer remains a leading cause of cancer mortality, mainly due to late 
diagnosis and resistance to current therapeutic treatments (Neoptolemos et al. 2018). 
Depending on the conditions of patients, different therapeutic strategies such as surgery, 
radiotherapy, chemotherapy or combinations thereof are used. Surgical resection 
remains a critical procedure in the pancreatic cancer management, despite the fact that 
only a small number of patients (10%) receive standard resection in the time of diagnosis 
(Strobel et al. 2019). For patients with early stage (I and II) resectable pancreatic cancer, 
curative surgery remains the best option (Shaib et al. 2007), followed by gemcitabine 
(GEM) plus capecitabine (CAP) adjuvant chemotherapy. The recent ESPAC-4 trial 
established GEM-CAP adjuvant therapy over GEM monotherapy for patients with 
resected pancreatic cancer and the 5-year overall survival rate was around 30% 
(Neoptolemos et al. 2017), (Khorana et al. 2017). For borderline resectable or locally 
advanced pancreatic cancer, neoadjuvant chemotherapy is proposed, although more 
evidence from randomized phase III trials are needed (Gillen et al. 2010). The ongoing 
four-arm randomized ESPAC-5F trial compares immediate surgery with GEM-CAP, 
FOLFIRINOX and chemoradiotherapy (ISRCTNregistry 2014). For patients with 
metastatic pancreatic cancer, palliative chemotherapy with FOLFIRINOX and 
gemcitabine + nab-paclitaxel is the mainstay treatment option (Mohammed et al. 2014), 
(Ryan et al. 2014). 
                
5.1.2.1 Gemcitabine: clinical applications and metabolism 
 
Figure 2. Molecular structure of gemcitabine. 
4-amino-1-(2-deoxy-2, 2-difluoro-β-D-erythro-entofuranosy l) pyrimidin-2(1H)-on. Fluorine atoms 
replace the hydrogen atoms on the 2′ carbon of deoxycytidine. 
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Even though the response rate to current chemotherapeutic treatment options is low, 
chemotherapy is used for PDA patients in any stage, especially in advanced stages when 
patients have lost the chance of operation (Vincent et al. 2011). Gemcitabine (2′,2′-
Difluoro-2′-deoxycytidine, dFdC) is a chemotherapeutic drug that has been approved by 
the Food and Drug Administration (FDA) for the treatment of unresectable pancreatic 
cancer in 1996 (Network 2019). In 1997, a randomized phase II trial proved the 
superiority of gemcitabine over fluorouracil (5-FU) as the clinical benefit response of 
GEM-treated patients (23.8%) was higher compared to the 5-FU-treated patients (4.8%) 
as well as the median survival time (5.6 months and 4.4 months, respectively) (Burris et 
al. 1997). Another phase II trial for advanced and metastatic pancreatic cancer has shown 
that the addition of capecitabine to the gemcitabine monotherapy improved the overall 
response rate and survival (Cunningham et al. 2009). Until now, gemcitabine has been 
the mainstay neo-adjuvant, adjuvant and palliative therapy for PDA and has been used 
for the treatment of various solid tumors including breast, lung and ovarian, however, a 
big obstacle is that resistance to gemcitabine occurs within the first weeks of treatment 
(Binenbaum et al. 2015).  
Regarding the chemical structure, GEM is a nucleoside analog in which the hydrogen 
atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms (Figure 2). The 
major uptake of gemcitabine takes place via the equilibrative and concentrative type of 
the nucleoside transporters (ENTs and CNTs, respectively). Once in the cell, the GEM 
prodrug (dFdC) is activated by an intracellular phosphorylation cascade initiated by the 
production of dFdCMP by deoxycytidine kinase (dCK). In turn, dFdCMP is converted 
by other pyrimidine kinases to its active diphosphate and triphosphate derivatives, 
dFdCDP and dFdCTP, respectively (Figure 3). The final metabolite, dFdCTP, is 
incorporated into the growing DNA chain as a normal nucleotide and leads to the 
inhibition of DNA synthesis (Binenbaum et al. 2015). Interestingly, levels of dFdCTP 
must comprise a sufficient proportion of the cellular pool of deoxyribonucleotides 
(dNTPs) in order to be efficiently incorporated into DNA and the NTPs pool is 
maintained by the enzyme ribonucleotide reductase (Liang et al. 2017). An additional 
self-potentiation mechanism of gemcitabine includes the binding of dFdCDP to the 
active site of ribonucleotide reductase leading to a decreased activity and synthesis of 
the dNTPs, which will further enhance the incorporation of dFdCTP into the DNA and 




Figure 3. Gemcitabine metabolism pathway (adapted and modified from (Liang et al. 2017)). After 
uptake of gemcitabine (dFdC) by the nucleoside transporters (hENT/hCNT), the GEM prodrug is 
converted to the dFdC monophosphate (dFdCMP) by deoxycytidine kinase (dCK). Afterwards, dFdCMP 
is converted to diphosphate (dFdCDP) and triphosphate (dFdCTP) metabolites by nucleoside 
monophosphate /diphosphate kinase (NMPK/NDPK). dFdCTP incorporates in the DNA causing 
inhibition of DNA synthesis and induction of apoptosis. dCTP is an endogenous competitor of dFdCTP 
or DNA-incorporation, and is produced by ribonuclease reductases (RR). 
5.2 Sulforaphane 
 
5.2.1 Chemical structure and bioavailability 
Epidemiological studies indicate that higher consumption of broccoli and other 
cruciferous vegetables of the Brassicaceae family are correlated with a lower cancer risk 
including PDA and cancer of the breast, lung, kidney, colon, rectum and prostate (Herr 
et al. 2013), (Kim and Park 2009). Brassicaceae are unique compared to other plants in 
their high content of glucosinolates (-thioglucoside N-hydroxysulfates), which is a 
class of sulfur-rich metabolites with more than 120 unique amino acid side chains (Herr 
and Buchler 2010), (Bayat Mokhtari et al. 2018). A focus has been placed on the 
glucosinolate glucoraphanin [4-(methylsulfinyl) butyl glucosinolate], which is found in 
high concentration in broccoli and its sprouts. 60-80% of glucoraphanin is converted 
upon plant tissue damage (e.g. chewing) to its active form, the isothiocyanate 
sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)-butane], by hydrolysis mediated 
by the β-thioglucosidase enzyme myrosinase or by the microbiota of the human colon. 
After being absorbed by the cells of the intestinal epithelium, sulforaphane is 
metabolised through the mercapturic acid pathway. This process involves its initial 
conjugation with glutathione, while the N-acetylation is important for the subsequent 
excretion of sulforaphane from the body through the urine, already few hours after 





5.2.2 Sulforaphane and cancer 
5.2.2.1 Mechanisms of action 
Sulforaphane is one of the best studied bioactive agents with chemopreventive properties 
and is proven to induce detoxifying of carcinogens, anti-oxidation, cell cycle arrest, 
apoptosis and epigenetic regulation, while inhibiting angiogenetic and metastatic 
progression (de Melo et al. 2018), (Bayat Mokhtari et al. 2018), (Tortorella et al. 2015). 
Inhibition of NF-B signaling: Initiation of inflammatory response is related to the 
nuclear factor kappa B (NF-κB) pathway. NF-κB is an important transcription factor 
ubiquitously found in all cell types and present in the cytoplasm in resting condition (Jost 
and Ruland 2007). In PDA, sulforaphane was shown to normalize increased NF-κB 
signaling by inhibiting transactivation-potent NF-B subunit c-Rel (Figure 4), which led 
to repression tumor stem cell features and increase of the sensitivity to cytotoxic drugs 
(Kallifatidis et al. 2009), (Rausch et al. 2010), (Kallifatidis et al. 2011).  
Induction of apoptosis: Sulforaphane was demonstrated to enhance apoptosis in 
glioblastoma cell lines via upregulation of Bax, Bad, Bax/Bcl-2 ratio, cytochrome C and 
downregulation of Bcl-2 (Figure 4) (Zhang et al. 2016). In prostate cancer, sulforaphane 
was shown to induce apoptosis by upregulation of Bax, activation of caspases-3, -9 and 
-8 and downregulation of Bcl-2 (Singh et al. 2004). 
Epigenetic regulation: Inhibition of tumor progression by sulforaphane also involves 
the modulation of epigenetic mechanisms such as DNA methylation, histone acetylation 
and miRNAs (de Melo et al. 2018). Sulforaphane inhibits the activity of DNA 
methyltransferases (DNMTs) in prostate and breast cancer cell lines (Wong et al. 2014), 
(Lubecka-Pietruszewska et al. 2015), while the inhibition of histone deacetylases 
(HDAC) is linked to the sulforaphane-induced apoptosis (Bayat Mokhtari et al. 2018). 
Recent findings demonstrate that sulforaphane induces microRNA (miRNA) signaling 
to inhibit NF-κB signaling via binding to the 3′-UTR of the transactivation-potent NF-




Figure 4. Main chemopreventive mechanisms of sulforaphane (adapted and modified from 
(Tortorella et al. 2015)). Induction of apoptosis is mediated by the increased expression of Bax and Bak 
as well as caspase 3, 8 and 9 and decreased expression of Bcl-2. Upregulation of Cytochrome C (CytC) 
enhances apoptosis by inducing Reactive Oxygen Species (ROS) and the anti-inflammatory effect of 
sulforaphane is displayed through the suppressed activity of NF-B signaling. Sulforaphane inhibits the 
activity of DNA methyltransferases, histone acetylases (HDAC) and miRNAs. 
 
5.2.2.2 Pharmaceutical relevance of sulforaphane 
Sulforaphane is cancer preventive and possesses therapeutic efficacy in treatment of 
cancer and has shown promising results in both pre-clinical and clinical studies. Pre-
clinical in vivo studies showed that intraperitoneal injection of sulforaphane (4.4 mg/kg 
on day 4, 5 and 6) in nude mice carrying PDA xenografts inhibited the tumor growth 
(Kallifatidis et al. 2009). A pilot study with pulverized broccoli sprouts was performed 
in the surgery department of the Heidelberg University Clinic with 40 patients involved, 
suffering from advanced, non-resectable pancreatic cancer. The results indicated that the 
patients in the broccoli sprout group survived longer compared to the placebo group, 
although the results were not significant due to the small number of patients (Lozanovski 
et al. 2019). With regard to other types of cancer, a randomized phase II clinical trial in 
women with early diagnosed breast intraductal carcinoma (DCIS) proved a decreased 
proliferative rate in the broccoli sprout extract group compared to the placebo 





A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent 
prostate cancer there was a significant lengthening of the prostate-specific antigen 
doubling time in the sulforaphane treatment group (Alumkal et al. 2015).  
5.3 Gap junctions 
Gap junctions are intercellular channels, found in the plasma membrane, that allow the 
direct communication between the cytoplasms of adjacent cells. These membrane 
structures contain cluster of channels and enable an intimate way of cell communication 
symmetrically in both directions (Alberts 2008). Gap junctions allow the exchange of 
ions, electrical signals, fluorescent dyes, secondary messengers and small metabolites 
with a mass less than 1 kDa (Evans and Martin 2002), such as Ca2+, cyclic adenosine 
monophosphate (cAMP) and inositol 1,4,5-triphosphate (IP3) through a process called 
gap junctional intercellular communication (GJIC). 
 
5.3.1 Structure and functions  
Gap junctions are formed by a family of proteins called connexins. Connexins are 
transmembrane proteins and six of them can form a hemichannel or connexon. Two 
connexons are aligned in the plasma membranes of the two cells forming an intercellular 
junction and also maintain a distance between the two plasma membranes via separation 
gap of 2-3 nm (Laird 2006), (Alberts 2008). There are 21 different proteins in the 
connexin family. Each connexin has four transmembrane (TM) domains, which are 
connected via the intramolecular disulfide bonds of the two extracellular loops. 
Connexins also have cytoplasmic N- and C- termini and an extra intracellular loop that 
links the transmembrane domain 2 and 3. Even though the transmembrane domains, 
extracellular loops and N- terminus are relatively conserved among the different 
connexins, the cytoplasmic loop and C-terminus show a great variance in the sequence 
and length (Mese et al. 2007). The gene structure and the divergence of the cytoplasmic 
loop leads to subdivision of connexins to five groups (    and ). A common 
abbreviation for connexins includes the ‘GJ’ from gap junction, the group symbol and 
the order to discovery of the protein (e.g. Cx32 was the first connexin of −group, 
GJ) However, the widely used nomenclature for connexins is based on their predicted 
molecular weight (e.g. Cx26 is 26 kDa in size). Connexins are expressed in nearly every 




Gap junctions with different combinations of connexins also have different permeability 
properties. Connexons with different connexin isoforms are called heteromeric, while 
homomeric connexins express only one connexin isoform. The same principle applies 
for the gap junctions, as homotypic are junctions with the same connexons and 
heterotypic are with different ones (Nielsen et al. 2012). 
From the connexin family, the most extended studies have been conducted on connexin 
43 (Cx43), as it is the most ubiquitously expressed connexin in mammals. It was first 
identified and sequenced in 1987, as a first connexin from the −group and is encoded 
by the GJA1 gene (Laird and Lampe 2018a). Most connexins including Cx43 are co-
translationally integrated into the endoplasmic reticulum (ER). If Cx43 is correctly 
folded, it traffics to the Golgi apparatus, where it oligomerizes in connexons in the trans-
Golgi network. The delivery of connexons to the cell surface is facilitated by 
microtubules via transport vehicles. Connexons could be permeable to small molecules 
exchange with the extracellular matrix until their docking on the gap junction plague. 
Prior to their lysosomal degradation, gap junctions are internalized into connexosomes 
(Figure 5) (Musil and Goodenough 1993), (Naus and Laird 2010). GJIC can be regulated 
by various stimuli including gap junction assembly and turnover and posttranslational 
connexin phosphorylation (Lampe and Lau 2004). In the case of Cx43, the 17 kDa C-
terminus is extensively phosphorylated at 21 different phosphorylation sites containing 
serine or tyrosine residues mainly by protein kinase C (PKC), casein kinase 1 (CK1) and 
mitogen-activated protein kinase (MAPK) (Axelsen et al. 2013).  
 
5.3.2 Gap junctions and cancer 
The first link between gap junctions and tumorigenesis was established in 1966 where 
the electrical coupling and metabolic cooperation was found to be defect in liver tumor 
cells compared to healthy hepatocytes (Loewenstein and Kanno 1966). Further studies 
revealed the loss of GJIC in several tumors (McNutt and Weinstein 1969), (Johnson and 
Sheridan 1971). After the discovery and characterization of connexins in the late 1980s, 
there were extended studies about the role of connexin expression in tumor progression. 
In most of the solid tissue human cancers, connexin expression is lost in the early stages 
suggesting a tumor suppressive role, while their role in the late stages is more complex 
as cancer cells seem to restore connexin expression levels in order to achieve tumor 
progression and metastasis (Naus and Laird 2010), (Aasen et al. 2016).  
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The tumor suppressive mechanism of connexins is mainly GJIC-dependent and involves 
the molecules exchange between normal cells and cancer cells, but can also be GJIC-
independent. 
In a normal tissue condition, the presence of connexins is necessary for the formation of 
gap junctions, the establishment of GJIC and exchange of specific metabolites. In a 
cancer tissue, connexins act as tumor suppressors and therefore inhibit the proper 
formation of gap junctions and the exchange of metabolites. This leads to an autonomous 
cell behavior and tumor progression (Naus and Laird 2010). In the case of Cx43, it was 
proven to act as tumor suppressor in colorectal, melanoma and breast cancer cells (Sirnes 
et al. 2012) , (Tittarelli et al. 2015),(Banerjee 2016). Several studies correlated low Cx43 
expression with poor prognosis in patients with pancreatic, prostate, colorectal and 
breast cancer (Benko et al. 2011), (Liang et al. 2010), (Teleki et al. 2014).  
 
5.3.2.1 Gap junctions and therapeutic potential 
The lack of intercellular communication lead to autonomous behavior of cancer cells, 
which results in failure to respond to cellular regulation mechanisms and chemotherapy 
resistance. Chemotherapeutic drugs and their metabolites can diffuse from cell-to-cell 
through the gap junctions enabling better therapeutic efficacy through bystander effect 
(Aasen et al. 2016). Bystander effect refers to the observation that chemotherapeutic 
drugs and their metabolites can diffuse from treated tumor cells to surrounding non-
treated tumor cells amplifying the cytotoxicity of the drugs. It was originally described 
in the ganciclovir (GCV) suicide gene therapy (Pitts 1994) and has also been 
documented with other drugs including gemcitabine (Cottin et al. 2010), (Garcia-
Rodriguez et al. 2011). Enhancing the GJIC is a therapeutic strategy that can increase 
the bystander effect and therefore the chemotherapy efficacy (Figure 5). In pancreatic 
cancer the bioactive agent sulforaphane has been shown to restore GJIC and gemcitabine 





Figure 5. Life cycle and therapeutic strategies on connexins and gap junctions (Adapted and 
modified from (Laird and Lampe 2018b)). Connexins (Cxs) are integrated in the endoplasmic reticulum 
and, if corrected folded, they enter the secretory pathway and reaching the plasma membrane where they 
can form the gap junction channels. Cxs oligomerize into connexons either in the endosplamic reticulum 
or at more distal sites including the trans-Golgi network. The transfer of connexons to the plasma 
membrane is conducted via transport vehicles and the transport is mediated by microtubules. Purple boxes 
refer to the therapeutic strategies with Cxs and gap junctional intercellular communication (GJIC) that are 
already mentioned such as increasing GJIC (4) or inhibition of connexin (Cx) expression levels. Blue 
boxes refer to future developments that can lead to better therapeutic results. For example, not only 
inhibition but also upregulation of Cx genes can be beneficial for cancer treatment (1) as well as the 
maintenance of the stability of GJs (Burris et al. 1997).  
 
5.4 MicroRNAs 
MicroRNAs (miRNAs) are small (19-25 nucleotides) evolutionary conserved, 
noncoding RNA molecules whose main function is to regulate gene expression through 
translational repression, mRNA decay or direct mRNA degradation by targeting its 3′-
untranslated region (3′-UTR) (Bartel 2009), (Slotwinski et al. 2018). miRNAs were first 
identified in C.elegans where the miRNA lin-4 inhibited the expression level of LIN-14 
protein (Lee et al. 1993) and the miRNA let-7 inhibited the expression of the LIN-41 
protein (Reinhart et al. 2000) by the complementary targeting of the 3′-untranslated 
region (3′-UTR). Based on the last release of the miRBase database, there are 2654 




5.4.1 Biogenesis and regulation 
In the nucleus, miRNAs are first transcribed either by RNA polymerase II or by RNA 
polymerase III into pri-miRNAs (Lee et al. 2004). Pri-miRNAs are long transcripts that 
consist of hairpin-like miRNA precursors. Pri-miRNAs are cleaved to pre-miRNAs by 
Drosha endonuclease and its binding partner DGCR8, which form the microprocessor 
complex (Lee et al. 2003. The 60-70 nucleotides precursor product (pre-miRNA) is then 
exported to the cytoplasm from the nucleus processed by Exportin-5 and Ran-GTP 
(Winter et al. 2009). The loop structure of the pre-miRNAs is further cleaved to a 
miRNA duplex by the RNAse III enzyme Dicer, which is interacting with the double-
stranded RNA binding protein TRBP (Tar RNA binding protein), PACT (protein kinase 
R-activating protein) and Argonaute family proteins (Ago1/2) (Gregory et al. 2005). 
From the miRNA duplex, the single guide strand is incorporated into the RNA-induced 
silencing complex (RISC) and is used to identify target mRNAs. Based on the 
complementarity of the guide miRNA strand with the mRNA transcript, there will be 















Figure 6. Canonical pathway of miRNA biogenesis (Slotwinski et al. 2018). 
 
5.4.2 miRNAs involved in cancer 
miRNAs influence numerous cancer-related processes in a tissue-specific manner, such 
as proliferation, apoptosis, migration, invasion, and drug resistance (Acunzo et al. 2015). 
The first documentation of miRNA abnormality in cancer was in 2002 where the miR-
15 and -16 were observed to be absent or downregulated in most of the chronic 
lymphocytic leukemia (CLL) patients due to the chromosomal loss of the 13q14 (Calin 
et al. 2002). Further studies showed that these 2 miRNAs regulate the BCL-2 expression 
in CLL and, as a result of the chromosomal depletion, the upregulation of BCL-2 leads 
to increased cell survival and tumorigenesis (Cimmino et al. 2005). Based on their 
regulation of tumor suppressors or oncogenes, miRNAs can be classified as oncogenic 
miRNAs (their overexpression leads to the inhibition of tumor-suppressor mRNA) or 
tumor-suppressing miRNAs (their downregulation leads to the induction of oncogene 
mRNA) (Kong et al. 2012). The study from Takamizawa et al. suggested let-7 as tumor-
suppressing miRNA, as its reduced expression correlated with shorter survival in lung 
cancer patients (Takamizawa et al. 2004). MiR-21 has been identified as oncogenic 
miRNA, as inhibition of miR-21 expression led to increased cell death in glioblastoma 
cells (Chan et al. 2005). In pancreatic cancer, many different miRNAs are involved in 




The function of miRNAs as tumor suppressors or oncogenes in PDA can vary even 
among the signaling pathways and the genes involved. For instance, the expression of 
miR-181b and miR-21 in PDA, which both regulate the expression of BCL-2, is different 
as miR-181b is documented to be downregulated, while miR-21 is upregulated (Sun et 
al. 2015). In the case of let-7 and miR-96, they both act as tumor-suppressing miRNAs 
by regulating the KRAS oncogene (Watanabe et al. 2009), (Yu et al. 2010).  
 
5.4.2.1 miRNAs and Cx43 
Regulation of connexin expression involves, except post-translational phosphorylation, 
additional modulating factors such as peptides, antibodies and miRNAs (Aasen et al. 
2016). Several studies have detected the inhibition of Cx43 expression at a post-
transcriptional level by miRNAs in different types of cancer as summarized in Table 2. 
 
Table 2. miRNA candidates for Cx43 regulation in cancer 
miRNA Symbol Cancer Type References 
miR-20a Prostate cancer (Li et al. 2012) 
miR-221/222 Glioblastoma (Hao et al. 2012) 
miR-125b Glioma (Jin et al. 2013) 
miR-200a Breast cancer (Ming et al. 2015) 













5.5 Aim of the study 
Previous studies in our group showed that sulforaphane enhanced Cx43 expression and 
restored the defective gap junctional intercellular communication in highly malignant 
and gemcitabine resistant pancreatic cancer cells (Forster et al. 2014). The first part of 
my thesis focuses on identifying the underlying mechanism of action of sulforaphane, 
which leads to gap junction activation and thereby increases gemcitabine sensitivity. The 
hypothesis of this project is that miRNA regulation is involved in the induction of gap 
junctional intercellular communication and Cx43 expression and this regulation 
increases gemcitabine cytotoxicity in pancreatic cancer. The major aim of this project 
is to identify a sulforaphane-regulated miRNA candidate and validate its function in gap 
junctional intercellular communication, Cx43 expression and tumor progression in vitro, 
in vivo and ex vivo. 
   
The second part of my thesis involves the biological evaluation of seven unprecedented 
derivatives of sulforaphane in pancreatic cancer and other tumor entities. The 
hypothesis of this project is that chemical modifications of sulforaphane could increase 
its therapeutic potential against pancreatic cancer. The major aim of this project is to 
evaluate the anti-cancer potential of these new sulforaphane derivatives with the least 
side effects in vitro and in vivo and, subsequently, compare the activity and underlying 
molecular mechanisms of the most effective derivatives to the original sulforaphane.
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6. Materials and Methods 
6.1 Materials  
6.1.1 Equipment and consumables  
6 well plates (Cell Star®) 
24 well plates (Cell Star®)  
Greiner bio-one, Austria 
Greiner bio-one, Austria 
96 well plates (Cell Star®) Greiner bio-one, Austria 
Analytical balance (Mettler P220) Mettler Toledo, Switzerland 
Blotting chamber Starlab, Belgium 
Thermal Cycler Bioer Technology, China 
BMG FLUO star OPTIMA Microplate 
Reader 
BMG LABTECH GmbH Germany 
Cell counter–ZTM Series 
Cell counter tubes 
Beckman Coulter, USA 
Beckman Coulter, USA 
Centrifuges  
-Biofuge 15 R Heraeus, Hanau 
-Capsulefuge PMC-060 TOMY, Fremont, USA 
-Cytospin 4 Thermo Scientific, USA 
-Varifuge 3.0 R Heraeus, Hanau 
Centrifuge tubes (15 ml and 50 ml) TPP, Switzerland 
Cell scraper Greiner Bio-one, Austria 
Cell culture plates  TPP, Switzerland 
Cell culture dishes TPP, Switzerland 
CO2 incubator  MS Laborgeräte, Germany 
Cryotubes Nunc, Denmark 
Digital motor breeder Poultry Farm Hockenberger, 
Eppingen, Germany 
Electrophoresis power supply Biotec Fisher, Germany 
Electrophoresis Semi-Dry Blotters Starlab, Belgium 
Electrophoresis unit Bio-Rad, USA 
Eppendorf Thermomixer comfort Eppendorf, Germany 









Gloves latex powder free Technomed, France 
Ice machine (AF80) Scotsman, USA 
Incubator-Digital motor breeders Siepmann, Germany 
Immobilon®-P Transfer membrane 
(Pore size 0.45 µm) 
Millipore, USA 
Lab freezers (-20°C, -80°C) Liebherr, Germany 
Laminar Flow Hood, HERA safe Heraeus Instruments, Germany  
Leukosilk® tape BSN medical, Germany 
Light microscope 
Mr. Frosty Freezing Container 
Leica, Germany 
Thermo Fisher, USA 
NanoDrop® Spectrophotometer 
Needles Gr20, grey, 27G, 0.4 x 22 mm 
Needles yellow, 20G, 0.9 x 40 mm 
NanoDrop Tech, USA 
BD, USA 
BD, USA 




pH-meter (pH 538) WTW, USA 
Pipette controller, comfort 
Polystyrene Round-bottom Tube with                               
Cell-Strainer Cap 
IBS Integra, Switzerland 
Neolab, Germany







Step One TM Real Time PCR system 
Thermanox plastic coverslips 
Applied Biosystems, USA 
Thermo Scientific, USA 
Thermo mixer Eppendorf, Germany 
Tissue culture dishes, Greiner bio-one, Austria 
Tissue culture flasks, T-75, T-150 TPP, Switzerland 
Vortexer (REAX2000)  Heidolph, Germany 
Water bath Kottermann, Germany 
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6.1.2 Media and supplements for cell culture  
DMEM High Glucose (4.5 g/l) Sigma-Aldrich, USA 
DNase/RNase free water Sigma-Aldrich, USA 
Dimethylsulfoxide (DMSO, >99%) AppliChem, Germany 
Dulbecco's Phosphate Buffer Solution (PBS) Invitrogen, USA 
FBS (Fetal Bovine Serum) Sigma-Aldrich, USA 
HEPES Buffer Solution (1M) PAA Laboratories, Austria 
Lipofectamine 2000 Invitrogen, USA 
Opti-MEM™ I Reduced Serum Medium  Thermo Fisher, USA 
RPMI-1640 without Phenol Red and L-
glutamine 
C.c.pro, Germany 
StemPro™ Accutase™ Cell Dissociation 
Reagent 
Thermo Fisher, USA 
Trypsin-EDTA (0.25%) Sigma-Aldrich, USA 
Water–Aqua ad injectabilia Braun, Germany 
 
6.1.3 Chemical agents and enzymes  
7-AAD (7-aminoactinomycin D) Thermo Fisher, USA 
2-Propanol Sigma-Aldrich, USA 
Acetone Sigma-Aldrich, USA 
Acrylamide stock solution Sigma-Aldrich, USA 
Ammonium persulfate (APS) Carl Roth, Switzerland 
Bovine Serum Albumin (BSA) 
Calcein AM Viability Dye  
CellTracker™ Red CMTPX Dye 
Chloroform 
DAPI (4,6-diamidino-2-phenylindole)                                                                       
New England Biolabs, USA 
Thermo Fisher, USA 
Thermo Fisher, USA 
Sigma-Aldrich, USA 
Sigma-Aldrich, USA 





EDTA-Disodium Sigma-Aldrich, USA 
Ethanol Sigma-Aldrich, USA 
Formalin Carl Roth, Switzerland 
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Gemcitabine Pharmacy, Heidelberg University 
Hospital 
Glycerol Appli Chem, Germany 
Glycine Appli Chem, Germany 
Goat serum Alexis, Germany 
Hydrochloric acid (HCl) J.T.Baker, Deventer, Netherlands 
Hematoxylin solution, Mayers 
Ketanest 25 mg/ml 
Lämmli sample buffer 4x 
Lucifer Yellow CH dilithium salt 
Magnesium Chloride (MgCl2)                                
Sigma-Aldrich, USA 
Pfizer, New York, USA 
Bio-Rad, USA  
Sigma-Aldrich, USA 
Carl Roth, Switzerland 
Methanol Carl Roth, Switzerland 
mirVana™ miRNA Inhibitor 
mirVana™ miRNA Inhibitor, Negative 
Control 
Thermo Fisher, USA 
Thermo Fisher, USA 
MTT Sigma-Aldrich, USA 
Paraformaldehyde (37%) Merck, Germany 
Potassium chloride (KCl) Merck, Germany 
Potassium dihydrogen phosphate (KH2PO4) Merck, Germany 
Protease inhibitor cocktail tablets 
Proteinase K 
Carl Roth, Switzerland 
Qiagen, Germany 
Protein ladder-Page RulerTM Fermentas, USA 
SDS pellets Carl Roth, Switzerland 
Sheep serum  Jackson ImmunoResearch, USA 
Sodium chloride (NaCl) 
Sodium citrate (Na3C6H5O7) 
Carl Roth, Switzerland 
Carl Roth, Switzerland 
Sodium hydroxide (NaOH) Carl Roth, Switzerland 
TEMED Merck, Germany 
Tris Merck, Germany 
Tween-20 Sigma-Aldrich, USA 
 
6.1.4 Kits 
Avidin-Biotin Blocking Kit Linaris, Germany 
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BCATM protein Assay Kit Thermo Fisher, USA 
BCIP/NBT Alkaline Phosphatase (AP) 
Substrate Kit  
Clariom D Assay 
VECTOR Laboratories, USA 
 
Thermo Fisher, USA 
Dual-Luciferase Reporter Assay System Promega, Germany 
GeneChip™ miRNA 4.0 Array Thermo Fisher, USA 
High-Capacity cDNA Reverse Transcription 
Kit 
Thermo Fisher, USA 
Lipofectamine™ 2000 Transfection Reagent Thermo Fisher, USA 
miRNeasy Mini Kit Qiagen, Germany 
miRCURY LNA™ microRNA ISH 
Optimization Kit (FFPE) 
EXIQON, Denmark 
PE Annexin V Apoptosis Detection Kit I  BD Biosciences, Germany 
PMirTarget_GJA1_3UTR_firefly OriGene, USA 
Pgl4.73[hRluc/SV40] Promega Germany 
RNeasy Mini Kit Qiagen, Germany 
TaqMan® MicroRNA Assay Thermo Fisher, USA 
TaqMan® MicroRNA Reverse Transcription 
Kit  
Thermo Fisher, USA 
TaqMan® Universal Master Mix Thermo Fisher, USA 
Pancreas cancer tissue array PA961c US Biomax INC., USA 
Lipofectamine® 2000 Reagent Thermo Fisher, USA 
VECTASTAIN Elite ABC HRP Kit  
ZytoChem-Plus HRP polymer kit with AEC 
Vector Laboratories, Inc, USA 
Zytomed Systems, Germany 
 
6.1.5 Buffers and solutions 
All buffers were prepared in distilled water unless otherwise specified. 
 
FACS Buffer                            500 ml PBS 
                                       2% FCS 
                                       2 mM EDTA  
 
10% APS  1 g Ammonium persulfate 
 
Adding ddH2O up to 10 ml 
 
1 M Tris-HCl 24.2 g Tris 




1.5 M Tris-HCl  36.32 g Tris 
 200 ml ddH2O pH 8.8 
  
10 PBS 2 g KCl 
 2 g KH2PO4 
 14.41g Na2HPO4
.2H2O 
 80 g NaCl 
 
Adding ddH2O up to 1L 
 
10% SDS  10 g SDS 
 
Adding ddH2O up to 100 ml 
 
MTT stock solution 
 






100 ml 1 PBS 
 2.930 g Glycine (39 mM) 
 5.810 g Tris (48 mM) 
 0.375 g SDS (0.0375% w/v) 
 200 ml Methanol (20%) 
 
Adding ddH2O up to 1 L 
 
Chicken PBS 7.2 g NaCl 
 0.37 g KCl 
 0.23 g CaCl2 
 
Made up to 1 L with ddH2O 
 

















10 x AP Buffer 
 
 
87.6 g NaCl (1.5 M) 
12.1 g Tris (100 mM) 
1 g NaN3 
Adjust volume with ddH2O up to 1L 
and pH to 7.5 
 
5 ml of 1M Tris-HCl 
2 ml of 0.5 M EDTA 
0.2 ml of 5M NaCl 
Adjust volume with ddH2O up to 1 L 
and pH to 7.4, autoclaving 
 
175.3 g NaCl 
88.2 g Sodium Citrate 
Adding ddH2O up to 1 L and 
autoclaving 
 
1 M Tris 
1 M NaCl 






Adjust volume with ddH2O up to 1 L 
and pH to 9.5 and autoclave (prepare 1 
MgCl2 buffer first and add to the Tris-




Antibodies for flow cytometry  
Annexin V, FITC-conjugated 
Human Connexin43/GJA1 APC-Conjugated 




Thermo Fisher, USA 
R&D Systems, Germany 
R&D Systems, Germany 
 
 
Antibodies for immunohistochemistry or immunofluorescence 
Anti-Cx43 rabbit polyclonal, 1:100 
Anti-pan cytokeratin monoclonal, 1:400 
Cell Signaling, USA 
Sigma-Aldrich, USA 
Anti-Ki67, rabbit, monoclonal, 1:200 Abcam, Cambridge, UK 
Anti-Caspase-3, mouse, monoclonal, 1:200  Novus, USA 
Anti-mouse-IgG, AlexaFluor 488-conjugated 
(Goat, polyclonal, immunofluorescence (IF), 
dilution 1:400) 
BD Pharmingen, Heidelberg, 
Germany 
Anti-rabbit-IgG, AlexaFluor 488-conjugated  
(Goat, polyclonal, IF, dilution 1:400) 
BD Pharmingen, Heidelberg, 
Germany 
Anti-mouse-IgG, AlexaFluor 594-conjugated 
(Goat, polyclonal, for IF, dilution 1:400) 
BD Pharmingen, Heidelberg, 
Germany 
Anti-rabbit-IgG, AlexaFluor 594-conjugated  
(Goat, polyclonal, for IF, dilution 1:400) 
Alkaline phosphatase-conjugated digoxigenin 
antibody (sheep polyclonal, for in situ 
hybridization (ISH), dilution 1:500) 
 
BD Pharmingen, Heidelberg, 
Germany 




6.1.7 Cell culture 
All the established cancer cell lines and the immortalized non-malignant pancreatic 
ductal cell line CRL-4023 were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA, USA).  
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The gemcitabine-resistant cell line BxGEM was selected from parental BxPC3 cells as 
previously described (Fan et al. 2016). The cells were cultured in DMEM/high glucose 
(Sigma-Aldrich, Missouri, USA) supplemented with 10% heat-inactivated FCS (Sigma-
Aldrich) and 25 mmol/L HEPES (PAA Laboratories GmbH, Pasching, Austria). Jurkat 
cells were cultured in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% 
heat-inactivated FCS (Sigma-Aldrich) and 25 mmol/L HEPES (PAA). Mycoplasma 
detection tests were performed for the cultured cells monthly (PlasmoTest, InvivoGen, 
San Diego, USA). All cell lines were authenticated from a commercial institution 
(Multiplexion, Heidelberg, Germany).  
 
6.1.8 Preparation of stock solutions 
D,L-Sulforaphane and the GJ inhibitor Oleamide (Sigma Aldrich) and the  sulforaphane 
derivatives were dissolved in DMSO to a stock concentration of 100 mM. Gemcitabine 
solution (126 mM, Lilly Deutschland, Bad Homburg, Germany) was freshly diluted in 
DMEM medium to a 100 µM stock. The fluorescent dyes CellTracker Red (CTR) 
CMTPX (Thermo Fisher Scientific, Dreieich, Germany) and Calcein-AM (Thermo 
Fisher Scientific) were dissolved in DMSO to a stock concentration of 10 mM. DMSO 
was used as a vehicle control for all experiments. Each stock aliquote was used only 
once immediately after thawing. 
 
6.2 Methods  
6.2.1 Cell culture maintenance 
Thawing cells  
A vial of cells was taken from the -150°C freezer and placed in the 37°C water bath for 
1 to 2 minutes until cells were thawed. After sterilizing the vial with 70% ethanol, cells 
were pipetted into a 15 ml tube containing 9 ml pre-warmed complete DMEM medium. 
The cells were centrifuged at 1500 rpm for 5 min. After centrifugation, the supernatant 
was discarded, the cell pellet was resuspended with 10 ml of complete DMEM medium, 
placed into a T-75 flask and incubated at 37°C with 5% CO2. 
 
Passaging cells 
When cells reached 80 to 90% confluence in flasks, they were passaged. After discarding 
the culture medium, 5 ml of PBS were added to wash the cell monolayer. 
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One ml trypsin/EDTA was pipetted into the T-75 flask and was put back into the 
incubator for 5 to 10 minutes. Afterwards, adding complete DMEM medium terminated 
the digestion, the cells were resuspended with medium for 4-5 times, to avoid the 
creation of cell clumps. Then the cells were put into a 15 ml tube and centrifuged at 1500 
rpm for 5 min. In between, the number of cells was calculated using the Z2™ Coulter 
Counter® System. The cell pellet was thoroughly resuspended with 10 ml complete 
medium containing 10% FCS.  
 
Freezing cells  
Long-term culturing is prone to genetic drift for immortalized cell lines, or mycoplasma 
contamination. Therefore, it is very important to freeze cells as a stock to preserve them 
for long-term usage. The principle of freezing cultured cells is to make stock at a high 
concentration and at as low passage number as possible. For that reason, cells were 
washed once with 5 ml 1× PBS and trypsinized. Afterwards, cells were resuspended in 
medium, centrifuged at 1500 rpm for 5 min and supernatant was discarded. Aliquots of 
3×106 to 1×107 cells were well resuspended in 900 μl FCS and 100 μl sterile DMSO, 
transferred into labeled cryotubes and immediately put in the Mr. Frosty freezing 
container in order to get a constant decrease in the temperature at a rate of 1°C/min. 
Subsequently, cryotubes were transferred to the -80°C freezer. Twenty-four hours later, 
cryotubes were transported to the -150°C freezer. 
 
6.2.2 Cell viability assay  
Measurement of cell viability and proliferation was performed by the MTT assay. The 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) substrate was 
prepared in a physiologically balanced solution, added to cells in culture, usually at a 
final concentration of 0.5 mg/ml (stock 5 mg/ml), and incubated for 1 to 4 hours. Viable 
cells with active metabolism convert MTT into a purple colored formazan product with 
an absorbance maximum near 570 nm. Dead cells cannot convert MTT into formazan 
and therefore purple color appearance in the well indicates viable cells. Twenty-four 
hours prior to treatment, PDA cells were seeded at a density of 4×104 to 6×104/ml in 96-
well plates. After corresponding transfection or treatment, 10 µl MTT stock was added 
to each well. Subsequently, the 96-well plates were incubated for 4h in an incubator at 
37°C and 5% CO2.  
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After completely removing media, 200 µl pre-warmed DMSO were added. The plate 
was shaken until all the blue crystals were completely solubilized. The optical density 
of each well was detected at 560 nm with an ELISA reader. 
 
6.2.3 Patient tissue 
A paraffin-embedded pancreatic cancer tissue array including TNM, clinical stages and 
pathology grade was obtained from BioCat GmbH-Assay ID: PA961c (Heidelberg, 
Germany/US Biomax, Inc., Rockville, Maryland, USA). 
 
6.2.4 Double-dye flow cytometry assay 
The degree of intercellular communication via GJs was examined by a double-dye flow 
cytometry assay as previously described (Cottin et al. 2010; Czyz et al. 2000). Briefly, 
the cells were seeded at a density of 8×104 cells/well in 6-well cell culture plates and 
were left untreated or treated with sulforaphane, oleamide or both for 24h. Donor and 
recipient cell populations were differently labeled with calcein-AM (a GJ-permeable 
dye) and CellTracker Red (a GJ-impermeable dye) in serum- and phenol red-free RPMI 
medium (C.c.pro, Oberdorla, Germany), respectively (Table 3). After 30 min at 37°C, 
the cells were washed with PBS, donor cells were harvested, added to the top of the 
recipient cells and co-incubated at a ratio of 1:10 (donor: recipient) for 1-2h (Figure 7). 
The calcein transfer to CellTracker Red-labeled cells through GJs was evaluated by 
analyzing the fluorescence intensity of the cells with a BD FACSCanto II flow cytometer 
(BD Biosciences, Heidelberg, Germany) and FlowJo software (BD Biosciences). 
Similar experiments were also conducted after transfection of the cells with mirVanaTM 





               
 
Figure 7. Schematic representation of the double-dye flow cytometry assay. Adapted from (Fonseca 






Table 3. Fluorescent dyes for double-dye flow cytometry assay 
Reagent and Company Solvent Stock solution 
Calcein-AM, cell-permeant dye 
Thermo Fisher  
5.02 µl DMSO     
 
   10 mM 
 
Cell-Tracker Red CMTPX dye 
Thermo Fisher 
7.28 µl DMSO      10 mM 
          
6.2.5 Microinjection of Lucifer Yellow 
The microinjection assay is a widely used method, which is allowing the introduction of 
compounds into the cells via iontophoresis. These compounds allow us to trace the 
degree and pattern of cell communication through GJ. The GJ-permeable fluorescent 
dye Lucifer Yellow (Sigma Aldrich) is easily injected by iontophoresis, highly 
fluorescent and diffuses through the cell rapidly. To investigate GJ communication, 
8×104 BxGEM cells were seeded on 35-mm dishes and after 24h treated with 10 µM 
sulforaphane and 50 µM oleamide or both. Before the measurement, the samples 
containing Oleamide were treated once again to maintain the gap junction blockage. The 
2.5% stock solution of Lucifer Yellow was diluted 1:5 with ddH2O. The tip of a 
homemade ultrathin glass pipette was positioned in the intracellular space of a single cell 
after microscopic observation. Measuring the membrane potential via a wire in the 
pipette and a ground electrode in the culture medium controlled the position of the 
pipette. Lucifer Yellow was injected with customized iontophoresis software for 90 s at 
a constant current of 10 nA. Fluorescence microscopy and video recording documented 
the distribution of Lucifer yellow to the surrounding cells. The mean gray values of the 
fluorescent intensity of the injected and direct neighboring cells were evaluated using 
customized image data processing software (Histo 3.0, University Hospital Heidelberg, 
Germany). 
 
6.2.6 Flow cytometry detection of gemcitabine bystander effect 
For the gemcitabine bystander effect experiments, cells were seeded at a density of 2×104 
cells/well in 24-well cell culture plates. Subsequently, the cells were left untreated or 
treated separately with gemcitabine, sulforaphane, oleamide or a combination of the 
reagents for 24h. Next, the untreated cells were stained with the red fluorescent dye 
CellTracker Red, as described in the double-dye flow cytometry assay paragraph.  
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The treated cells were detached and seeded in 96-round well cell culture plates together 
with the CellTracker Red-labeled untreated cells at a ratio of 1:1. After 48h co-
incubation, the cells were stained with the 7-aminoactinomycin D (7-AAD, BD 
Biosciences) dye to investigate cell viability and analyzed with a BD FACSCanto II flow 
cytometer (BD Biosciences) and FlowJo software (BD Biosciences). Similar 
experiments were also conducted after transfection of the cells with mirVanaTM inhibitor 
of hsa-miR30a-3p and mirVanaTM Negative Control inhibitor served as a control. 
 
6.2.7 miRNA and mRNA microarray analysis  
All products and procedures strictly referred to the manufacturer’s instructions according 
to the protocol of TaqMan® Small RNA Assays and TaqMan® Gene Expression Assays. 
Major steps were sequentially performed as explained in the following chapters.  
 
6.2.7.1 RNA and miRNA isolation and concentration measurement 
The miRNeasy Mini Kit and the RNeasy Kit was used for miRNA and mRNA isolation, 
respectively, according to the manufacturer’s instructions (Qiagen, Hilden, Germany). 
All procedures were performed according to kit manual and the final products were used 
instantly or were frozen at -80C for future use. NanoDropTM 2000 Spectrophotometer 
was used for the concentration measurement.  
 
6.2.7.2 mRNA and miRNA expression profiling 
The microarray analyses were carried out at the Microarray-Analytic Center of the 
Medical Faculty Mannheim. Briefly, 500 ng mRNA or miRNA was checked by quality 
control and the concentration was measured again. Human miRNA profiling was 
analyzed using the Affymetrix GeneChip miRNA 4.0 Array (Thermo Fisher Scientific) 
and human mRNA profiling was measured by Clariom D Assay (Thermo Fisher 
Scientific).  
 
6.2.7.3 mRNA and miRNA data interpretation 
The raw fluorescence intensity values were normalized applying quantile normalization 
and RMA background correction. One-Way ANOVA was performed to identify 
differential expressed miRNAs and genes.  
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Volcano plots (Figure 8) and heat maps were created using a commercial software 
package SAS JMP10 Genomics, version 6, from SAS (SAS Institute, Cary, NC, USA). 
A false positive rate of a=0.05 with FDR correction was taken as the level of significance. 
The Ingenuity® Pathway Analysis software (Suppipat et al. 2012)(Qiagen) using the 
microRNA target filters and the online platform mirWalk (http://zmf.umm.uni-
heidelberg.de/apps/zmf/mirwalk2/) were used for identification of putative miRNA 
binding sites of genes of interest (Figure 9). The Target Mining Option provided the 
option of predicting target gene interaction of a list of miRNAs and the different and 
common gene interactions can be displayed as graph nodes (Sticht et al. 2018).  
 
 
Figure 8. Volcano plot showing gene distribution (adapted and modified from 
https://galaxyproject.github.io/training-material/topics/transcriptomics/tutorials/rna-seq-viz-with 
volcanoplot/tutorial.html). Gene distribution. On the y-axis, the P-values and significance were plotted. 






Figure 9. IPA filtering tool to confidently identify mRNA targets of miRNAs. Adapted from IPA data 
sheet. 
Gene Set Enrichment Analysis (GSEA) was used to evaluate whether defined lists of 
genes exhibit a statistically significant bias in their distribution within a ranked gene list 
using the software GSEA (Subramanian et al. 2005).  Pathways of different cell 
functions were obtained from public external databases (KEGG, 




Figure 10. Gap junction KEGG pathway map 
6.2.7.4 Transfection with miRNA inhibitors 
PDA cells were seeded on 6-well, 24-well or 96-well plates and cultivated until they 
reach 60 to 70% confluency. Hsa-miR-30a-3p mirVana® miRNA inhibitor (Catalog Nr: 
4464084) or mirVanaTM Negative Control inhibitor (Catalog Nr: 4464076) were used 
for transfection in a concentration of 30 nM (Table 4). Briefly, 30 nM miR30a-3p or 
negative control inhibitor were diluted in Opti-MEM™ I Reduced Serum Medium. In 
parallel, Lipofectamine™ 2000 transfection reagent was added to Opti-MEM™ I 
Reduced Serum Medium (Table 4), mixed well and incubated at RT for 5 min. The 
diluted inhibitor and lipofectamine transfection complexes were mixed and incubated 
for 20 min at RT, according to lipofectamine® 2000 reagent manual. 
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Afterwards, the built-up miRNA-lipofectamine complexes were transferred to 
corresponding wells and incubated at 37°C in a CO2 incubator for 24h. After 4 to 6h 10% 
FCS was added to the serum-free medium in order to maintain the viability of the cells. 
 
Table 4. Transfection with miRNA inhibitors 






96-well 100 µl (50 µl +25 µl +25 µl) 30 nM 0.15 µl  0.25 µl 
24-well 500 µl (400 µl +50 µl +50 µl)  30 nM 0.75 µl 1 µl 
6-well 2 ml (1500 µl + 250 µl+ 250 µl)   30 nM 3 µl 5 µl 
V1= serum free medium, V2 and V3=Opti-MEM® Medium with diluted miRNA inhibitors and 
Lipo2000 respectively. 
         
6.2.7.5 Reverse transcription of mRNA to cDNA 
MRNA was extracted with RNeasy Kit. Hundred ng mRNA were used for reverse 
transcription with High-Capacity RNA-to-cDNA™ Kit. The reverse transcription 
reaction mix was prepared on ice according to Table 5.  
Consequently, the reverse transcription reaction mix was incubated at 37C for 60 min, 
heat-inactivated at 95C for 5 min and kept at 4C. The cDNA was used immediately 
for real-time PCR or stored at -80C for further use. 
 




2× RT (Reverse Transcription) Buffer 
20× RT Enzyme Mix 




Total volume 20 µl 
   
6.2.7.6 Reverse transcription of miRNA to cDNA 
RNA was isolated with the miRNeasy Mini kit and 10 ng were subjected to cDNA 
synthesis using the TaqMan MicroRNA Reverse Transcription Kit. The reverse 
transcription reaction mix was prepared on ice according to Table 6. The reverse 
transcription reaction mix was first denatured at 16C for 30 min, then annealed at 42C 
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for 30 min and elongated at 85C for 5 min. The cDNA was used immediately for real-
time PCR or stored at -80C for further use. 
 
Table 6. Components of Reverse Transcription reaction mix (miRNA to cDNA) 
 
Component Master mix volume for 15 µl 
reaction 
100mM dNTPs (with dTTP) 
MultiscribeTM Reverse Transcriptase, 50 U/µl 
10x RT Buffer 







Total volume 7 µl 
 
6.2.7.7 Real-time quantitative PCR 
TaqMan® Universal Master mix was used for real-time quantitative PCR. The qPCR 
reaction mix was pipetted in triplicate according to the protocol and transferred to a 48-
well plate (Table 7). After the plate was tightly sealed with film, it was centrifuged for 
3 min at 3000 g at room temperature to remove bubbles. Then the real time PCR was set 
up according to Table 8. The small nuclear RNU6B was used as an endogenous control 
and GADPH served as a reference gene for normalization. 
 
Table 7. Reaction compounds of Real-Time PCR  
Component Volume 
20x microRNA or Expression Primer  


















Table 8: Cycling conditions for real-time PCR 
Step Time Temperature 















   
6.2.8 Preparation of chicken eggs and transplantation of established PDA cell lines  
Fertilized eggs were obtained from a local ecological hatchery (Geflügelzucht 
Hockenberger, Eppingen, Germany). All eggs were from genetically identical hybrid 
Lohman Brown (LB) chickens. The delivery day was set as Day 0, the eggs were 
immediately washed with 70% warm ethanol. Then, the fertilized eggs were incubated 
in a digital motor breeder at 37.8°C and 45-55% humidity with a rotating mechanism. 
Four days after incubation, 4 ml albumin were removed with a 21 gauge needle and 5 
ml syringe to detach the embryonic structures from the eggshell, then a hole was made 
over the eggshell in order to observe the embryonic viability and to apply a treatment. 
The hole was covered with Leukosilk® tape, and the eggs were put back into the 
incubator for embryonic development without rotation. On day 9 of embryonic 
development, 7×105 cells/egg were transplanted at a ratio of 1:1 with Matrigel onto the 
chorioallantoic membrane (CAM) of fertilized chicken eggs, and five days later, on day 
14, 100 nM of gemcitabine or 10 µM of sulforaphane and derivatives, diluted in PBS, 
were injected intravenously (i.v) into the CAM vessels (50 µl/egg). The bleeding was 
stopped with a cotton bud. Control eggs were injected with 50 µl PBS alone (Figure 11). 
Tumor resection and evaluation of tumor growth was conducted at day 18. Tumor 
volumes were evaluated 3-dimensionally by a USB microscope camera (eScope, Oitez, 
Hongkong) and digital image editing using a customized mount. The volume was 
calculated using three main diameters obtained by digital image processing with ImageJ 
(NIH, Bethesda, MD, USA) and the formula V= 4/3 × π × r3; r=0.5 × √(d1 × d2 × d3), 




Figure 11. Experimental procedure of xenograft treatment on fertilized chicken eggs. (A) Image 
depicting the intravenous injection into the blood vessels of the CAM depending on the experiment. (B) 
The bleeding caused by the injection was stopped with a cotton bud. (C) After stopping the bleeding, eggs 
were sealed again with Leukosilk® tape and turned back to the incubator. (D) The chick is sacrifised after 
injecting intravenously (i.v) 0.1 ml of Ketanest. (E) Day 18, the last possible point for resection of 
xenografts before hatching. (F) Egg xenografts after resection.       
6.2.9 Dual-luciferase reporter assay 
Cells were seeded at a density of 2×104 cells/well in 24-well plates and co-transfected 
with 30 nM mirVanaTM negative control or miRNA inhibitor, 12.5 ng/well of pRL 
Renilla luciferase reporter plasmid (Promega, Mannheim, Germany) and 25 ng/well 
firefly luciferase pMirTarget vector (OriGene, Rockville, USA) either empty (Catalog 
Nr: PS100062) or expressing Cx43 3′-UTR (Catalog Nr: SC216210). The cells were 
lysed in 1X Passive Lysis Buffer of the Dual-Luciferase Reporter Assay System 
(Promega) 24h post-transfection. Firefly and Renilla luciferase activities were measured 





Immunohistochemistry on 6-µm frozen or paraffin-embedded tissue sections was 
performed using the VECTASTAIN Elite ABC HRP Kit, ZytoChem-Plus HRP polymer 
kit with AEC according to the manufacturer’s instructions. Anti Cx43 (Cell Signaling), 
pan-cytokeratin (Sigma-Aldrich), Ki67 (Abcam) and Caspase-3 (Novus) were used as 
primary antibodies. The negative control was prepared without primary antibody. The 
goat anti-rabbit or anti-mouse biotinylated IgG were used as secondary antibodies for 
the detection. The signal was amplified with the ABC kit. AEC kit was used as a 
chromogen. Samples were counterstained with haematoxylin, dehydrated in graded 
alcohol, rinsed in xylene and mounted in Entellan. The analysis of the stainings was 
done using a Leica DMRB microscope at a 400x magnification and pictures were taken 
with the SPOTTM FLEX 15.2 64 Mp shifting pixel digital camera (Diagnostic, 
Instruments, Inc. USA) and analyzed with the SPOT Basic/Advanced 4.6 Software. 
 
6.2.11 Apoptosis assay 
PE Annexin V Apoptosis Detection Kit I was used to analyze cell death with flow 
cytometry analysis. PE Annexin V staining precedes the loss of membrane integrity, one 
of the main characteristic events of apoptosis, while 7-AAD is a dye that binds to 
intracellular DNA when the cells are non-viable. Cells that are only Annexin V positive 
are considered to be in early apoptotic stage and cells that are Annexin V and 7-AAD 
positive indicate late apoptosis and necrosis. With refer to the experimental protocol, 10
×104 cells/ml were seeded on 6-well plates and, 24h later, transfected with miRNA 
inhibitors, according to the experimental design, or treated with sulforaphane derivatives. 
Afterwards, the cells were transferred in 96-well round bottom plates and stained with 
Annexin V for 15 min at RT following by 2 washing steps. 7-AAD was added to the 
samples 10 minutes before the measurement. Proper staining controls were set. Finally, 
the cells were analyzed with a BD FACSCanto II flow cytometer and FlowJo software. 
 
6.2.12 In situ hybridization 
Detection of miR30a-3p expression in patient tissue sections was accomplished using 





To obtain strong miRNA signal localized in tumor cells, I incubated the tissue with the 
ISH substrate overnight and sterilize tips and pipettes in order to diminish the RNAses 
effect. Experiment was performed on a microarray microscopy slide covering 91 human 
pancreatic cancer and 5 normal tissues. Briefly, the sections were deparaffinized in Roti-
Histol and serial dilutions of 100% ethanol, then demasked with proteinase K (20 mg/ml) 
for 15 min at 37°C, which allows the access of LNA probes to hybridize with the 
miRNA, following by dehydration of the slides. Hybridization was done for 2h at 54°C 
using 50 nM of the miR-30a-3p digoxigenin-labeled LNA detection probe 
(5'CUUUCAGUCGGAUGUUGCAGC3’, # 339111) and 0.3 nM of the LNA U6 
snRNA as a positive control. After stringent washes the bound LNA-probes were 
detected with alkaline phosphatase-conjugated digoxigenin antibody and NBT/BCIP as 
substrate. Sections were mounted using Roti-Mount FluorCare. 
 
6.2.13 Colony formation assay 
Cells were collected and seeded in 6-well plates at a density of 2-4×104 cells/well, 
followed by treatment with sulforaphane or sulforaphane derivatives for 24h. Next, cells 
were centrifuged and re-plated at a low density of 400 cells/well for AsPC-1 and 800 
cells/well for BxPC3 in 6-well plates in triplicate. After incubation for two weeks at 
37°C without changing medium, cells were fixed with 2 ml 3.7% paraformaldehyde 
(PFA) for 10 min followed by 2 ml 70% ethanol for another 10 min and one wash with 
1⨯ PBS. Cells were then washed 3 times with dH2O and stained with 0.05% Coomassie 
blue for 5 min. Subsequently, cells were washed with dH2O and dried overnight. A 
colony was defined as a spot comprising more than 50 cells. The number of colonies was 
quantified under a dissecting microscope and the percentage of plating efficiency was 
calculated (plating efficiency of non-treated cultures=1) (Kallifatidis et al. 2009), 
(Kallifatidis et al. 2011). To investigate the potential for formation of secondary 
colonies, cells were collected from the colonies above and equal numbers of cells were 
reseeded. Colonies were calculated in the same manner. 
 
6.2.14 Life span assay 
Life span analysis of the Caenorhabditis elegans (C. elegans) N2 worms (CGC, 




L4-stage worms (n=100/group) were picked up and transferred into 60 mm medium-
sized plates (TPP, Trasadingen, Switzerland) containing S medium and E. coli OP50 as 
a food supply (Stiernagle 2006).  
 
Sulforaphane, SF102, SF134 in a concentration of 400 µM or DMSO alone, were added 
to S Basal medium for 48h. The lifespan was examined by documenting the amount of 
live and dead worms and they were transferred daily to new E. coli plates until they did 
not lay any more eggs. Worms that died of causes other than aging such as internal 
hatching or vulva protrusion were excluded from the analysis. Survival curves were 
created using the Kaplan-Meier analysis. 
 
6.2.15 Chemical synthesis of sulforaphane derivatives 
Seven derivatives of sulforaphane were synthesized and kindly provided by Prof. 
Carsten Bolm and his co-workers (Institute of Organic Chemistry, RWTH, University 
of Aachen). The monoaza racemate derivatives of sulforaphane (SF85 and SF101) or its 
sulfone (SF86, SF102, SF113, SF134, and SF135) were prepared, which differ from the 
parent compound by formal substitutions of the sulfinyl (S = O) group by either 
sulfimidoyl (S(NR)) or sulfoximidoyl (S(O)(NR)) moieties. The R substituent at the 
nitrogen is acetyl (as in SF85 with S(NAc) and SF86 with S(O)(NAc)), 
pentafluorobenzoyl (as in SF101 with S(NC(O)C6F5) and SF102 with 
S(O)(NC(O)C6F5)), methyl (as in SF113 with S(O)(NMe)), trifluoroacetyl (as in SF134 
with S(O)(NCOCF3)), and carbamoyl (as in SF135 withS(O)(NCONH2)). 
 
6.2.16 Statistical analysis 
The data obtained with established cell lines are presented as the means ± SD from at 
least three separate experiments, which were performed at least in triplicate. The 
significance of the data was analyzed with Student t-test corrected for multiple 
comparisons with the Bonferroni-Holm method. The Pearson Product-Moment 
Correlation was performed to measure the linear correlation between two variables X 
and Y. For the immunohistochemistry or immunofluorescence experiments, the 
expression intensity and percentage of positive cells were determined by counting the 
number of differentiated cells in 10 fields of view for each group.  
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For evaluation of Kaplan Meyer analysis of C. elegans life span, the standard chi-square-
based log-rank test was used. For the miRNA microarray data, the JMP software 
provided by SAS Institute (Heidelberg, Germany) was used.  P<0.05 was considered 




7.1 Sulforaphane-mediated inhibition of miR30a-3p enhances gap 
junctional intercellular communication, thereby increasing 
gemcitabine cytotoxicity in pancreatic cancer 
 
7.1.1 Sulforaphane induces GJIC 
To address the effect of sulforaphane on gap junction (GJ) formation, a double-dye flow 
cytometry assay for gap junctional intercellular communication (GJIC) was performed 
with 2 established PDA cell lines, BxGEM and PANC-1. The rationale for choosing 
these two cell lines was firstly based on their low or impaired Cx43 expression, which 
is associated with absent GJ function, and secondly their resistance to chemotherapy. 
(Forster et al. 2014), (Dovmark et al. 2017). First, donor cells were loaded with calcein, 
a GJ-permeable green fluorescent dye, and then co-incubated with recipient cells, which 
were loaded with the GJ-impermeable and membrane-resident red fluorescent dye 
CellTracker Red (CTR), at a ratio of 1:10. As GJs are permeable to calcein, the transfer 
of green fluorescence from donor to recipient cells and the appearance of double-positive 
cells indicate successful GJIC. The percentages of single- and double-stained cells were 
quantified by flow cytometry (Figure 12A). The flow cytometry assay was conducted 
with the abovementioned PDA cells, which were left untreated or treated with 
sulforaphane in the presence or absence of the GJ inhibitor oleamide. After co-
incubation, the cells were analyzed, and double-positive cells were present in the right 
upper quadrant of the dot plot (Figure 12B). A calcein diffusion of approximately 11% 
was observed in control and oleamide-treated cells. Interestingly, sulforaphane treatment 
significantly increased calcein diffusion to 25% and 21% in BxGEM and PANC-1 cells, 
respectively. Sulforaphane and oleamide co-treatment decreased the percentage of 
double-positive cells (15% in BxGEM and 18% in PANC-1 cells), suggesting that 
sulforaphane enhances the transfer of calcein by opening the GJs. To further highlight 
this assumption, I microinjected sulforaphane-treated or untreated BxGEM cells with 
the GJ-permeable fluorescent dye Lucifer Yellow and measured the distribution to 
neighboring cells by time-lapse microscopy (Figure 12C). For data analysis, the mean 
gray values of the fluorescence intensity of the injected and the direct neighboring cells 
were evaluated using the customized image data processing software, Histo 3.0.  
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Cells treated with sulforaphane showed a significant increase in Lucifer Yellow 
distribution up to 20% compared to untreated cells and to cells treated with oleamide 
alone. Oleamide co-treatment significantly reduced the sulforaphane-mediated Lucifer 
Yellow transfer to 9%, most likely by the inhibition of the sulforaphane-mediated 










Figure 12: Sulforaphane increases GJIC. (A) Experimental design of the double-dye flow cytometry 
assay. BxGEM and PANC-1 cells were labeled with 1 µM calcein-AM or 5 µM CellTracker Red.Next, 
calcein-loaded cells were plated on top of the CTR-stained cells and co-incubated in a donor/target ratio 
of 1:10. After co-incubation, cells were detached and analyzed by flow cytometry. (B) White bars: 
Untreated cells (CO), Oleamide-treated cells (Ol). Black bar: Sulforaphane-treated cells (SF). Black bar 
with stripes: co-treatment with sulforaphane and oleamide (SF+Ol). In the flow cytometry dot plots, the 
percentages of double-positive cells (upper right) and single-red labeled cells (down right) are shown. (C) 
Representative images from fluorescence and light microscopy with Lucifer Yellow-injected cells are 
displayed. The mean of gray values per group was calculated and shown in the diagram. Scale bar indicates 
20 µm. The means ± SD are shown in the diagrams. *P<0.05, **P<0.01. 
 
7.1.2 Sulforaphane potentiates the gemcitabine bystander effect through GJIC 
To gain knowledge about the influence of sulforaphane on gemcitabine cytotoxicity, I 
performed the well-established method of gemcitabine bystander effect. The aim was to 
identify whether sulforaphane increases gemcitabine-induced cell death by opening GJs 
and increasing the uptake of gemcitabine metabolites by neighboring cells. BxGEM and 
PANC-1 donor cells were treated with gemcitabine, sulforaphane and oleamide alone or 
in combination. Twenty-four hours later, the cells were co-incubated in a ratio of 1:1 
with CTR-labeled but otherwise untreated BxGEM or PANC-1 target cells. After forty-
eight hours of co-incubation, the cells were labeled with 7-AAD and cell death was 
evaluated by flow cytometry. The presence of double-fluorescent target cells (CTR+/7-
AAD+) indicates a successful bystander effect (Figure 13A, Figure S1A). The number 
of double-positive BxGEM target cells was approximately 9% in gemcitabine- and 
sulforaphane-single-treated cells, and the percentage increased to 11% by co-treatment, 
whereas co-incubation with oleamide significantly decreased the percentage of double-
positive cells to 8%. PANC-1 target cells treated with gemcitabine and sulforaphane 
together showed a significant increase of 28% compared to untreated target cells with 8% 
and oleamide co-treatment reduced the percentage of induction to 23% (Figure 13B). 
Representative microscopy images of cell cultures underline the results obtained by flow 
cytometry and demonstrate that blocking GJs by oleamide prevents cell death induced 











Figure 13. Sulforaphane enhances the gemcitabine bystander effect through GJs. Experimental 
design of the bystander effect assay. BxGEM and PANC-1 donor cells were left untreated (CO) or treated 
with 3 µM gemcitabine (GEM), 10 µM sulforaphane (SF), 50 µM oleamide (Ol) or a combination of the 
agents for 24h. Next, treated cells were co-incubated with untreated but CellTracker Red (CTR)-stained 
cells at a ratio of 1:1 (donor: target). After 48h of co-incubation, the cells were detached and stained with 
7-aminoactinomycin D (7-AAD), and cell death was evaluated by flow cytometry (B). Diagrams interpret 
the mean percentages of CTR+/7-AAD+ cells from three independent experiments. White bars: Untreated 
cells (CO), Oleamide-treated cells (Ol). Black bars highlight the percentages of GEM, SF, GEM+SF and 
GEM+SF+Ol groups. The means ± SD are shown. *P<0.05, **P<0.01. (C) The morphology of the cells 







7.1.3 Sulforaphane inhibits miR30a-3p and enhances Cx43 expression 
To investigate the underlying mechanism of sulforaphane-induced GJIC, I performed 
miRNA and gene microarray analysis. RNA was isolated from BxGEM cells, which 
were left untreated or treated with sulforaphane for 24h. Based on bioinformatics 
evaluation, 36 differentially regulated miRNAs with the highest statistical significance 
were selected (with -log10 p-Value of ≥ 2) and are shown in a heat map (Figure 14A). 
For further analysis, 6 out of 36 miRNA candidates were selected by in silico analysis 
and a literature search based on two selection criteria: downregulation by sulforaphane 
and relevance to GJs (Table S1). MiR30a-3p was chosen as the most relevant candidate, 
because is the only miRNA candidate predicted to regulate the expression of the GJA1 
gene that encodes the Cx43 protein (Figure 14B). The qRT-PCR results confirmed that 
the expression of miR30a-3p in BxGEM and PANC-1 cells was significantly decreased 
upon sulforaphane treatment (Figure 14C).  
 
To verify the influence of sulforaphane on Cx43 expression, a mRNA profiling array 
was performed with BxGEM cells treated as described above. From the gene microarray 
analysis, based on the criteria of significance and upregulation, a heatmap was created 
with GJA1 and the 10 most significantly upregulated GJ genes (Figure 15A). The 
expression profile and the interaction of these genes was analyzed by the KEGG search 
tool (Figure S2). The upregulation of GJA1 mRNA after sulforaphane treatment was 
confirmed in BxGEM and PANC-1 cells by qRT-PCR (Figure 15B). As the expression 
of connexins at the cell surface is essential for GJ formation and function, BxGEM cells 
were left untreated or treated with sulforaphane, and 24h later, these cells were stained 
with an APC-conjugated Cx43 antibody and analyzed by flow cytometry. Sulforaphane 





Figure 14. Sulforaphane inhibits miR30a-3p expression. (A) BxGEM cells were left untreated (CO) or 
treated with 10 µM sulforaphane (SF). Total RNA was harvested 24h later and used for GeneChip miRNA 
4.0 Array in triplicate. The heatmap presents the top 36 significantly regulated miRNAs after sulforaphane 
treatment and the names of the six most relevant candidates are shown. The red color marks high 
expression, and the green color marks low expression within a scale from 0.5 to -1, as indicated. (B) In 
silico analysis using IPA software and the keywords gap junctions, pancreatic cancer revealed 6 miRNA 
candidates with putative target sites in GJ genes. A table summarizes the significance (p-value) of the 
downregulation of the miRNA candidates after sulforaphane treatment and their GJ target genes. (C) 
BxGEM and PANC-1 cells were treated as described above, and 24h later, the RNA was harvested, and 
the fold change in miR30a-3p expression was determined by qRT-PCR and normalized to RNU6B. The 





Figure 15. Sulforaphane induces GJA1 expression and upregulation of Cx43 protein. (A) BxGEM 
cells were left untreated (CO) or treated with 10 µM sulforaphane (SF). Total RNA was harvested, 
followed by gene expression profiling in triplicate using the Clariom D Assay. The heatmap presents the 
top 11 upregulated GJ genes after sulforaphane treatment and the 2 most relevant genes are shown. (B) 
BxGEM and PANC-1 cells were treated as previously described, and RNA was harvested. The fold change 
in GJA1 expression was determined by qRT-PCR and normalized to GAPDH. The controls were set to 1 
(C) Cx43 surface protein expression levels were evaluated in BxGEM cells by flow cytometry analysis. 
Right: representative histogram plots. Left: Mean percentage Cx43 surface expression from three 
independent experiments. The means ± SD are shown. *P<0.05, **P<0.01. 
 
 
7.1.4 miR30a-3p inhibits Cx43 expression by binding to its 3′-UTR 
To obtain knowledge about the interaction of miR30a-3p and Cx43, I performed a search 
in the TargetScan database (Agarwal et al. 2015) to identify the putative binding sites of 
miR30a-3p on the Cx43 3′-UTR (Figure 16A). The next step was to prove the binding 





For this purpose, a commercially available luciferase reporter construct expressing the 
Cx43 3′-UTR was lipotransfected into BxGEM cells, and a firefly reporter construct or 
a Renilla control plasmid was co-transfected in the presence or absence of miR30a-3p 
mimic or a negative control mimic. Twenty-four hours after transfection, the luciferase 
activity was quantified using a luminescence microplate reader. I observed a 
significantly reduced luciferase activity of the Cx43 reporter upon co-transfection of the 
construct with miR30a-3p, which was not observed with the controls or miR30a-3p 
alone (Figure 16B), suggesting that miR30a-3p suppressed Cx43 mRNA expression. 
 
Figure 16. miR30a-3p inhibits Cx43 expression by binding to its 3′-UTR. (A) Two putative binding 
sites of miR30a-3p in the Cx43 3′-UTR are shown. (B) BxGEM cells were co-transfected with a firefly 
reporter construct of the Cx43 3′-UTR plasmid in the presence or absence of either 30 nM miR30a-3p 
(miR30) or a negative control (Neg. CO) inhibitor. The co-transfection of a Renilla luciferase (0.25 ng/μl) 
served as a control for equal conditions. Twenty-four hours after transfection, the expression of Renilla 
and firefly luciferase was detected. Firefly luciferase activities were normalized to Renilla luciferase 








7.1.5 Inhibition of miR-30a-3p induces GJIC and gemcitabine bystander effect 
To clarify whether sulforaphane enhances GJIC through inhibition of miR30a-3p, a 
double-dye flow cytometry assay was conducted with BxGEM cells, which were 
transfected with 30 nM mirVanaTM negative control or miR30a-3p inhibitors for 24h. 
Then, donor and recipient cells were labeled and co-incubated as described in paragraph 
7.1.1., The percentages of single- and double-stained cells were quantified by flow 
cytometry (Figure 17A). Calcein diffusion of 12% was observed in BxGEM cells after 
control transfection, whereas miR30a-3p inhibition significantly increased the 
percentage to 23% in a similar manner to sulforaphane treatment. To identify whether 
miR30a-3p transfection can influence the gemcitabine bystander effect, BxGEM donor 
cells were transfected with the negative control or miR30a-3p inhibitor and were 
additionally treated with gemcitabine, oleamide or a combination of both (Figure 17B). 
Twenty-four hours later, the cells were co-incubated with CellTracker Red-labeled 
untreated target cells and evaluated for cell death as mentioned in Figure 13A. The 
amount of double-positive BxGEM target cells was significantly higher in miR-
transfected cells compared to the control (19% and 13%, respectively). Gemcitabine 
treatment in miR-transfected cells significantly augmented cell death up to 33%, while 
oleamide treatment adequately decreased the percentage of dead target cells to 19% 
(Figure 17C and Figure S1B). Therefore, our data suggest that miR30a-3p suppression 




Figure 17. Downregulation of miR30a-3p increased the GJIC and gemcitabine bystander effect. 
BxGEM cells were lipofected with 30 nM miR30a-3p (miR30) or negative control (Neg. CO) inhibitors, 
followed by fluorescence labeling, co-incubation of the cells and flow cytometry analysis as described in 
Figure 13A. (A) The percentages of double-positive cells (upper right) and single-red labeled cells (down 
right) are shown. Bar graphs represent the percentage of double-positive cells and correspond to results 
from at least three independent experiments. (B) Experimental design of the bystander effect assay after 
miR30a-3p transfection. BxGEM donor cells were transfected with miR30a-3p (miR30) or negative 
control (Neg. CO) inhibitors and treated with 3 µM gemcitabine (GEM), 50 µM oleamide (Ol) or a 
combination of the agents for 24h. Next, treated cells were co-incubated with untreated but CellTracker 
Red (CTR)-stained cells in a ratio of 1:1 (donor: target). After 48h of co-incubation, the cells were 
detached and stained with 7-aminoactinomycin D (7-AAD), and cell death was evaluated by flow 
cytometry (C) Graphs showing the mean percentages of CTR+/7-AAD+ cells from three independent 






7.1.6 miR30a-3p decreases the tumor xenograft volume 
To evaluate the in vivo relevance of my findings, I performed xenograft studies using 
the fertilized chicken egg model, which has been successfully applied in my laboratory 
for many years (Zhao et al. 2018), (Bauer et al. 2014). BxGEM cells were lipotransfected 
with 30 nM negative control or miR30a-3p inhibitors, and at 24h post-transfection, the 
cells were transplanted onto the chorioallantoic membrane on day 9 of embryonic 
development. Five days later, 100 nM gemcitabine or PBS was injected into the 
chorioallantoic membrane vessels, and the tumor xenografts were resected on day 18. I 
measured the xenograft tumor size by calipers, and the mean sizes are displayed in a 
diagram (Figure 18A). The tumor size was decreased in the xenografts derived from 
miR30a-3p-transfected cells. Moreover, inhibition of miR30a-3p significantly enhanced 
gemcitabine cytotoxicity compared to the control or single miR30a-3p-transfected 
tumors. To evaluate Cx43 expression in xenograft tissues, I performed 
immunohistochemistry staining and evaluated the fluorescence intensity with ImageJ 
software (Figure 18B). MiR30a-3p-transfected tumors showed significantly higher Cx43 
expression, suggesting that inhibition of miR30a-3p induces chemotherapy competence 
in PDA xenografts most likely via Cx43. These results suggest that sulforaphane 
downregulates miR30a-3p expression, which in turn leads to upregulation of Cx43 




Figure 18. miR30a-3p decreases the volume of xenograft tumors. (A) BxGEM cells were lipofected 
with 30nM miR30a-3p (miR30) or a negative control (Neg. CO) and then seeded onto the CAM of the 
egg on day 9. Xenografts were treated with gemcitabine (GEM) or PBS on day 14 and were resected and 
analyzed on day 18. The control (CO) group refers to transfected xenografts that did not receive injection. 
Tumor volumes are presented as black dots, and the mean tumor volume is presented as black line for 
each experimental group. A representative image of a tumor xenograft growing on the CAM of a fertilized 
chicken egg (black arrow) is shown. (B) Frozen tissue sections were examined by immunohistochemistry 
and staining of Cx43. The cell nuclei were counterstained with DAPI (blue). The intensity of the 
immunofluorescence signal was quantified in 10 vision fields with ImageJ. The means ± SD are shown. 
**P<0.01. Representative images are shown on the right and positive Cx43 stainings (red) are marked 
(white arrows). (C) Scheme of sulforaphane-induced inhibition of miR30a-3p expression, which induces 






7.1.7 Correlation of miR30a-3p and Cx43 expression in PDA patient tissue 
To verify the clinical relevance of my findings, I detected the expression of miR30a-3p 
and Cx43 in a pancreatic cancer tissue array with 91 human pancreatic cancer tissues 
and 5 normal pancreatic tissues by in situ hybridization and immunohistochemistry, 
respectively (Figure S3). The expression patterns were evaluated by scoring the staining 
intensity and signal localization after microscopic observation, as presented in the 
scheme of the tissue array (Figure 19A). In PDA tissue, miR30a-3p expression was high, 
with the most positive signal found in ductal epithelium, whereas the expression in 
normal pancreatic tissue was low. On the contrary, normal pancreatic tissues expressed 
higher levels of Cx43 compared to PDA tissues (Figure 19B). The correlation of 
miR30a-3p and Cx43 expression was analyzed with the Pearson Product-Moment 
Correlation method and the representative scatter plot revealed a negative correlation 
with a p value of <0.01, suggesting that high miR30a-3p correlates with low Cx43 
expression in PDA tissue. A negative correlation was also observed for pathological 
grading and Cx43 expression with a p value of <0.01, suggesting that Cx43 expression 





Figure 19. Low Cx43 and high miR30a-3p expression correlate with malignancy. A paraffin-
embedded tissue microarray slide containing 91 cases of pancreatic cancer and 5 normal pancreatic tissues 
was used. The expression of miR30a-3p and Cx43 was detected by in situ hybridization (ISH) and 
immunohistochemistry (IHC), respectively. (A) The score of miR30a-3p and Cx43 expression was 
evaluated by using a semiquantitative scoring system based on the percentage of positive cells: high (3), 
medium (2), low (1) and absent (0). Six tissues of the microarray were either necrotic or damaged and 
therefore were excluded from the evaluation (thick black dot). (B) Positive miR30a-3p expression in PDA 
tissue (malignant) is shown in representative images. Arrows mark the localization of miR30a-3p, which 
is appeared to be light blue colored. Positive Cx43 expression in normal pancreatic tissue (normal) is 
shown in representative images. Arrows in the images highlight the localization of Cx43, detected as light 
red colored. (C) A scatterplot of miR30a-3p ISH and Cx43 IHC scores in the pancreatic tissues is shown. 
Pearson's correlation coefficient (r) = - 02911, p value (P) =0.0080. A scatterplot of Cx43 IHC scores and 
the correlation with pathological grading is depicted. Pearson's correlation coefficient (r) = - 0.3004, p 
value (P) =0.0049. All images were taken at 400x magnification and the scale bar indicates 50 µm. 
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7.2 Analysis of the therapeutic potential of sulforaphane derivatives in 
pancreatic cancer 
 
7.2.1 Chemical structure of the seven sulforaphane derivatives 
With the aim to produce sulforaphane-based derivatives with higher bioactivity, the 
group of Professor Bolm synthesized 7 racemate derivatives of sulforaphane, which 
differ from the parent compound by formal substitutions of the sulfinyl (S = O) group 








7.2.2 SF102 and SF134 are cytotoxic in all the evaluated tumor cells 
To investigate whether the 7 sulforaphane derivatives display cytotoxic properties, 
BxPC3, BxGEM, and AsPC-1 pancreatic cancer cells were left untreated or were treated 
with 10 or 30 µM sulforaphane or its derivatives SF85, SF86, SF101, SF102, SF113, 
SF134 and SF135. DMSO alone or untreated cells served as controls. Twenty-four hours 
after treatment, the cell viability was measured by MTT assay and documented by 
microscopy. Sulforaphane strongly reduced the viability in all cell lines compared to 
solvent DMSO controls or untreated cells, as expected (Figure 21A, B). The effects of 
SF102 were comparable to sulforaphane, whereas SF134 was less potent. All other 




Figure 21. SF102 and SF134 repress viability of PDA cells. (A) BxPC3, BxGEM, and AsPC-1 cells 
were left untreated (CO) or treated with 10 or 30 µM sulforaphane (SF) and derivatives 
(85,86,101,102,113,134,135). Twenty-four hours later, viability was measured by MTT assay. DMSO was 
used as a vehicle control. Data are means ± SD of at least three independent experiments. (B) BxGEM 
cells were treated, as described above, the morphology of the cells was observed and representative images 




The therapeutic effects of SF102 and SF134 were not restricted to pancreatic cancer cell 
lines, but also occurred in cancer cells from cervix, ovary, prostate, breast, colorectum, 
and lung, as well as in hepatocellular, neuroblastoma, T-cell leukemia and glioblastoma 




Figure 22. Sulforaphane derivatives repress viability in various cancer entities. All the tested cells 
were left untreated (CO) or treated with 10 or 30 µM sulforaphane 102 or 134 (SF102, SF134). Twenty-
four hours later, viability was quantified by MTT assay. DMSO was used as a vehicle control. Diagrams 
represent means ± SD of at least three independent experiments. *P<0.05, **P<0.01. P5: cervical cancer, 
OVM: ovarian cancer, PC3: prostate cancer, BT-20: breast cancer, SW707: rectal adenocarcinoma, IMR5: 
neuroblastoma, Jurkat: T-cell acute lymphoblastic leukemia, P693: lung carcinoma, HepG2: 
hepatocellular carcinoma, A172: glioblastoma. 
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7.2.3 SF102 and SF134 induce apoptosis 
To further elucidate whether SF102 and SF134 suppress viability via apoptosis, BxPC3, 
BxGEM, and AsPC-1 cells were left untreated or treated with sulforaphane, SF102 and 
SF134 for 24h. Next, cells were labeled with the PE-conjugated antibody against 
Annexin V and the fluorescent dye 7-aminoactinomycin D and analyzed by flow 
cytometry. The presence of double-fluorescent cells (Ann+/7-AAD+) indicates late 
apoptosis (Figure 23). Sulforaphane in a concentration of 10 or 30 µM induced a 
percentage of apoptosis around 30% in the most sensitive cell line BxPC3, whereas the 
effects in the chemoresistant cell lines BxGEM and AsPC-1 were marginal. However, 
SF102 induced significant apoptosis in these resistant cells of approximately 30% and 




Figure 23. SF102 and SF134 enhance apoptosis in PDA cells. BxPC3, BxGEM, and AsPC-1 cells were 
left untreated (CO) or treated with 10 µM sulforaphane (SF) and sulforaphane derivatives (SF102, SF134). 
After 24h, the cells were stained with PE-conjugated Annexin V and 7-AAD and then evaluated for cell 
death by flow cytometry. The percentage of double-stained cells (Ann+/7-AAD+) is an indication of late 
apoptosis. Bar graphs depict the percentage of Ann+/7-AAD+ cells that were analyzed by flow cytometry 
after treatment with 10 or 30 µM sulforaphane (SF) and sulforaphane 102 and 134 (SF102, SF134). The 







7.2.4 SF102 and SF134 diminish colony-forming capacity 
To study the ability of sulforaphane derivatives to interfere with clonogenicity, which is 
a typical tumor stem cell feature, BxPC3 and AsPC-1 cells were left untreated or treated 
with sulforaphane, SF102 and SF134. After 24h, a colony-forming assay was performed, 
and the number of surviving cells was evaluated by microscopy (Figure 24A). SF102 
and SF134 significantly reduced the number of colonies in chemoresistant AsPC-1 cells, 
although the effect of the original sulforaphane was more pronounced. In BxPC3 cells, 
SF102 was most potent in reducing colony formation, followed by sulforaphane or 
SF134 (Figure 24B). To test if the effect on the clonogenicity is long lasting, I isolated 
single live cells from the colonies and re-seeded them without additional treatment. In 
the resulting second generation, the number of colonies was further reduced compared 
to the first generation suggesting that SF102 and SF134 treatment eliminated the more 
aggressive, colony-forming, tumor stem-like cancer cells. 
 
 
Figure 24. SF102 and SF134 inhibit the colony forming ability of PDA cells. BxPC3 and AsPC-1 cells 
were treated as described above, followed by plating of the cells 24h later at a low density (BxPC-3: 500 
cells/well, AsPC-1:1000 cells/well) in 6-well plates. After two weeks, colonies were fixed with 3,7% PFA 
and Coomassie-stained. Colonies containing more than 50 cells were quantified under a dissecting 
microscope and photographed. (A) Representative images of fixed colonies are shown. (B) The percentage 
of plating efficiency was calculated and showed in the bar diagrams (plating efficiency of non-treated 
cultures was set to 1). Cells were harvested from non-fixed and non-Coomassie-stained duplicate plates 
of the first generation (1st Gen) of colony formation and re-plated at the same density in 6-well plates. 
Two weeks later, the clonogenic survival of the second generation (2nd Gen) was evaluated. The means 




7.2.5 SF102 and SF134 inhibit the growth of tumor xenografts in vivo 
To evaluate the in vivo relevance of my findings, I performed xenograft studies using 
BxPC3 or BxGEM cells that were transplanted onto the CAM of fertilized chicken eggs 
on day 9 of development. Five days later, sulforaphane, SF102, SF134 or a PBS control 
were injected into the CAM vessels and the tumor xenografts were resected on day 18. 
The size of each tumor was measured with calipers and the individual, as well as the 
mean, sizes are displayed in the diagrams (Figure 25A). The size of the BxGEM-derived 
tumors was significantly lower after treatment with SF102 compared to the control 
xenografts. The tumor suppressing effect of SF102 on BxPC3-derived xenografts was 
apparent, although the data were not statistically significant. To examine proliferation, 
xenograft cryosections were stained with the marker Ki67, followed by 
immunohistochemistry and evaluation of fluorescence intensity (Figure 25B). The 
quantification of Ki67 positive cells revealed that proliferation was significantly 
decreased to about 20% after SF102 treatment. Similarly, the cleaved fragment of 
activated caspase-3 was significantly upregulated in SF102-treated tumors indicating 




Figure 25. SF102 and SF134 reduce the volume of tumor xenografts. BxPC3 or BxGEM cells were 
seeded onto the CAM of the egg on day 9 of embryonal development. Xenografts were treated with 10 
µM sulforaphane (SF) and derivatives (SF102, SF134) on day 14. The tumor xenografts were resected on 
day 18, and the tumor volumes were calculated as described in the methods part. Control (CO) group 
refers to xenografts that have received an injection with PBS. (A) The volumes of individual tumors (black 
dots) and the mean tumor volume of each experimental group (black lines) are demonstrated in the 
diagrams. A representative image of a tumor xenograft on the CAM (black arrow) on day 18 is shown. 
Immunohistochemistry staining of the frozen tissue sections were conducted with (B) the proliferation 
marker Ki67 (brown) (C) the apoptosis marker “cleaved fragment of caspase-3” (Casp3, Red) and the 
epithelial marker pan-cytokeratin (PanCyt, green). All images were taken at 400x magnification and the 
scale bar indicates 50 µm. The intensity of the Ki67 and Casp3 immunofluorescence signal was quantified 




7.2.6 SF102 and SF134 had no adverse side effects on the lifespan of chicken 
embryos and C. elegans       
To further investigate whether SF102 and SF134 induce toxic side effects, the liver 
morphology of the chick embryos and their body weight at the day 18 of development 
were analyzed. As indicated by hematoxylin staining, no necrotic areas were detected in 
liver tissue (Figure 26A). Likewise, the body weight of chick embryos was around 12 to 
14 g without significant differences between groups (Figure 26B). To further rule out 
any side effects, I treated wild type C. elegans nematodes with sulforaphane, SF102, 
SF134 or the vehicle DMSO alone for 48h.  The survival of the worms was documented 
over a period of 35 days by Kaplan Meier analysis. I did not observe a shorter survival 
of worms after treatment with sulforaphane, SF102 and SF134 compared to the control 




Figure 26. Effect of SF102 and SF134 on C. elegans lifespan and chicken embryos. 
(A) Hematoxylin staining of embryonal liver sections of embryos derived from fertilized chicken eggs, 
which were treated as described above. The scale bar indicates 25 µm. (B) The mean embryonal weight 
of the chick embryos was determined by weighting and the means of 15 embryos per group ± SD are 
shown. (C) Wild type C. elegans worms were treated with sulforaphane (SF), SF102, or SF134 for 48h, 
or were left untreated (CO) and Kaplan Meier analysis was performed. SF102 significantly prolonged the 
lifespan of the nematodes compared to the control. A representative microscopy image from a C. elegans 
worm is shown on the right. The scale bar indicates 100 µm. 
 
 67 
7.2.7 Sulforaphane, SF102 and SF134 exhibit similarities and differences regarding 
microRNA signaling and target gene induction 
 
To further highlight the underlying signaling pathways responsible for the observed anti-
tumor effects of SF102 and SF134, miRNA microarray expression profiling and 
bioinformatics evaluation of potential target genes was performed. AsPC-1 cells were 
treated with sulforaphane, SF102 or SF134 or were left untreated and the RNA was 
isolated 24h later. In cooperation with Dr. Sticht, I identified 500 significant (P<0.05) 
and differentially regulated miRNAs compared to the control. As presented in the heat 
map, there were many similar clusters but also obvious differences in miRNA expression 
following sulforaphane, SF102 and SF134 treatment (Figure 27A). Next, the top 10 most 
significantly regulated miRNAs were evaluated in three comparison groups: (1) 
sulforaphane versus control, (2) SF102 versus control (3) SF134 versus control (Figure 
27B). Through this analysis, miR2278 was identified as common and most significant 
downregulated miRNA after sulforaphane, SF102 and SF134 treatment (Table S2). To 
identify further differences in miRNA expression between sulforaphane, SF102 and 
SF134, I created Volcano plots from the most significant differentially regulated 
miRNAs with –log10 p values >2 among the comparison groups mentioned above and 
an extra group, SF102 versus SF134.  MiR27b-5p and miR29b-1-5p were identified as 
the most interesting candidates, as they were downregulated after sulforaphane treatment 
compared to control, but upregulated by SF102 and SF134 compared to sulforaphane 
(Figure 27C). Interestingly, the comparison between SF102 and SF134 showed a small 
number of differentially regulated miRNAs. The miRNAs identified from the volcano 
plot comparisons were summarized in a Venn diagram and the names of the miRNA 
candidates were provided in a supplementary table (Figure 27D, Table S3). Altogether, 
the three miRNA candidates, miR228, miR27b-5p and miR29b-1-5p came out from the 
bioinformatic analyses as the most important candidates in order to differentiate the 









Figure 27. miRNA expression profiling and bioinformatic analysis detects common and different 
expression patterns induced by sulforaphane and sulforaphane, SF102 and SF134. (A) AsPC-1 cells 
were treated with 10 µM sulforaphane (SF), SF102, or SF134, or were left untreated (CO). Twenty-four 
hours later, RNA was isolated and analyzed by a GeneChip miRNA 4.0 Array in triplicates. The heatmap 
presents the top significantly regulated miRNAs after sulforaphane and its derivatives treatment. The red 
color marks high expression, and the green color marks low expression within a scale from 0.5 to -1, as 
indicated. (B) The 3 heatmaps present the top 10 significantly regulated miRNAs after sulforaphane and 
its derivatives treatment. MiR2278 is highlighted in red color (C) Volcano plots show the miRNA 
distribution. On the y-axis, the –log10 p value is plotted, whereas on the x-axis, the fold change is 
represented. (D) Venn diagram shows the distribution of differentially expressed miRNAs among three 
groups compared: SF-CO, SF102-SF and SF134-SF. The overlapping region identified two miRNAs, 






To obtain information about target genes regulated by the three candidate miRNAs, a 
bioinformatic analysis using the Target Mining tool of mirWalk platform was performed. 
After providing the list of miRNAs and generating the search output based on the 
prediction of miRNA-target gene interactions, the data are depicted as a network plot. 
This search resulted in 309 target genes that are individually or commonly regulated by 
the 3 miRNA candidates (Figure 28A). To follow up on our previous studies showing 
that sulforaphane normalizes enhanced NF-B activity by miRNA signaling (Kallifatidis 
et al. 2009), (Yin et al. 2019), the abovementioned 309 target genes were filtered for NF-
B signaling and the selected genes were displayed in a separate network plot (Figure 
28B). MiR2278 is predicted to regulate the highest number of NF-B-related target 
genes, which partially overlap with genes that are regulated by miR27b-5p and miR29b-






Figure 28. Identification of NF-B related miRNA-target genes. (A) Using the Target Mining option 
of the mirWalk online platform, 309 target genes of miR2278, miR27b-5p and miR29b-1-5p were 
identified and displayed as a network graph. Each orange dot is associated to a target gene. The black lines 
symbolize e.g. the joint target gene CCDC141 of miR2278 and miR29b-1-5p, the joint target gene CREB5 
of miR-29b-1-5p and the joint target genes RPRD1A, CLMN, and LRRC8C of miR-2278 and miR27b-
5p. (B) A miRNA-target gene analysis with focus on NF-B signaling identified the most significantly 
NF-B-related target genes of miR29b-1-5p, miR2278 and miR27b-5p. TIRAP and DDX58 are target 
genes of miR2278 and miR29b-1-5p, CFLAR, ERC1 and PRKCB are target genes of miR2278 and 























































8.1 Sulforaphane induces gemcitabine cytotoxicity in PDA by the 
downregulation of miR30a-3p 
In this part of my thesis, I focused to elucidate the mechanism of action of sulforaphane-
induced gap junction formation and how the presence of gap junctions could further 
potentiate gemcitabine activity in PDA. I analyzed the involvement of miRNA signaling 
in sulforaphane-induced GJIC in PDA cells. MiR30a-3p was identified as a promising 
GJ-related candidate, whose downregulation either by sulforaphane or by transfection of 
miR30a-3p inhibitors enhanced gemcitabine sensitivity through GJ-related 
overexpression of Cx43 in vitro in PDA cells and in vivo in tumor xenografts derived 
from PDA cells. Patient tissue analyses revealed that high miR30a-3p expression 
correlates to low Cx43 expression, which could in turn associate with PDA staging. 
 
8.1.1 Sulforaphane enhances GJ function and gemcitabine bystander effect 
In this work I demonstrated that sulforaphane induced the GJIC in highly malignant PDA 
cells and this effect was clearly diminished when cells were co-treated with sulforaphane 
and the gap-junction inhibitor oleamide. This finding was consistent with former studies 
done in my laboratory (Forster et al. 2014). To prove the effect of sulforaphane on GJIC, 
I applied the well-established double-dye flow cytometry assay, which was used to study 
the function of GJs not only in PDA (Garcia-Rodriguez et al. 2011), but also in 
glioblastoma (Hitomi et al. 2015) and melanoma (Tittarelli et al. 2015).  
 
Sulforaphane has already been shown to induce the gemcitabine cytotoxicity in PDA 
cells via suppression of the highly aggressive cancer stem cells (Kallifatidis et al. 2011). 
Herein I presented that sulforaphane re-stored the chemosensitivity of PDA cells to 
gemcitabine this time through induction of GJIC. The GJ-specificity of the result was 
confirmed with the presence of the gap-junction inhibitor oleamide. In line with my 
results, Cottin et al. demonstrated that functional GJs are essential for the induction of 






To examine the gemcitabine bystander effect in PDA cells, I combined cell death 
analysis with double-dye flow cytometry to identify the percentage of dead and non-
pretreated target cells. The key advantage of this method compared to e.g., the MTT 
assay or microscopic observation (Cottin et al. 2010), (Garcia-Rodriguez et al. 2011), 
(Alexandre et al. 2007), is the specific quantification of dead target cells, which are 
recognized as double-fluorescent cells from the flow cytometer.  
A better combined effect of sulforaphane and gemcitabine combination compared to the 
single substances was observed in PDA cells. This was a major achievement because 
it did not only show that the cytotoxicity of PDA cells to gemcitabine was higher after 
sulforaphane treatment but also provided an alternative therapeutic option, in which the 
cytotoxic molecules can be transferred to PDA cells that do not receive initial treatment 
(Kandouz and Batist 2010).  
 
8.1.2 Sulforaphane augments Cx43 expression by inhibiting miR30a-3p expression 
Hereby I demonstrated that sulforaphane enhanced the Cx43 expression on the surface 
of PDA cells, an expected result linked to the activated GJs.  The tumor suppressive 
role of Cx43 in PDA and its significance for GJ function and cancer progression was 
previously documented (Forster et al. 2014), (Dovmark et al. 2017). Concerning 
chemotherapy bystander effect and Cx43 expression, my results correlated high Cx43 
expression with gemcitabine sensitivity in PDA. As a supporting evidence of these 
findings, high Cx43 expression was found to be important as well for paclitaxel 
cytotoxicity in ovarian carcinoma (Toler et al. 2006), while in breast cancer PQ1, a 
Cx43-enhancer, restored defective GJIC and counteracted cisplatin resistance (Ding and 
Nguyen 2012).  
 
The missing link between sulforaphane-induced restoration of GJIC and Cx43 
expression was identified and it involved miR30a-3p in the regulation of Cx43. My study 
is the first to show the regulation of Cx43 through miR30a-3p. The binding of miR30a-
3p to the Cx43 3′-UTR was demonstrated, suggesting that the reduction of miR30a-3p 
levels is directly involved in the modulation of Cx43 expression. These results explain 
one crucial mechanism, which has been first mentioned in our former study (Forster et 




In this study though, sulforaphane was shown to enhance the expression levels of Cx43 
protein, but did not upregulate Cx43 mRNA expression, in contrast to my current 
findings. This might be due to different experimental conditions regarding time points 
of sulforaphane treatment (6h in the former study and 24h in the actual study) and the 
Cx43 primers used. Whereas the former study used self-made PCR primers and 
conventional qRT-PCR conditions, the actual study used TaqMan ready-to-use primers 
and TaqMan PCR conditions.  
 
The high miR30a-3p expression in PDA cell lines is in line with the study of Zhang et 
al., although that study did not evaluate the function of the miRNA (Zhang et al. 2009). 
On the contrary, studies in hepatocellular carcinoma propose a rather tumor suppressive 
function of miR30a-3p, as its downregulation promotes invasion and metastasis (Wang 
et al. 2014). The exact reason for these opposing results is not clear, however it is 
assumed that the expression of miR30a-3p could be cancer and tissue type-specific. 
 
8.1.3 miR30a-3p inhibits gemcitabine resistance in vitro and in vivo 
Transfection with miR30a-3p inhibitors induced both GJIC and gemcitabine bystander 
effect and this result confirmed our main hypothesis that miR30a-3p is the underlying 
key regulator of sulforaphane for the induction of GJIC, Cx43 expression and 
gemcitabine sensitivity in PDA cells. Interestingly, I could observe a much stronger 
bystander effect after transfection with liposomes, which could possibly be explained by 
the fact that transfection itself induces background cytotoxicity (Wang et al. 2018). 
 
To confirm that administration of miR30a-3p could be effective in vivo, I used the 
fertilized chicken egg model for tumor xenotransplantation, because this system is an 
ethical alternative to experiments performed on mammals (Aleksandrowicz and Herr 
2015) and has been evaluated in several of our recent studies (Zhao et al. 2018), (Bauer 
et al. 2014), (Nwaeburu et al. 2017). A major advantage of the chicken egg model is its 
natural immunodeficiency because immunocompetence in birds develops only after 
hatching. Xenografts are transplanted to the CAM, usually on day 8 or 9 of development, 
when the blood vessel network is dense enough to support the growth of a tumor 
xenograft. Fast tumor growth and potential for drug delivery studies are major 





By the use of this model I confirmed my in vitro results and proved that miR30a-3p 
transfection decreased tumor growth and increased gemcitabine sensitivity of PDA 
xenografts, which were transfected in vitro and treated with gemcitabine in vivo. 
 
8.1.4 miR30a-3p and Cx43 expression in pancreatic cancer tissue 
To assess the clinical relevance of my results, a screening of miR30a-3p and Cx43 
expression in a pancreatic cancer tissue array with 96 normal or malignant patient tissue 
sections was performed. My data showed that the expression of miR30a-3p in malignant 
tissue is higher than in normal tissue on average. These findings are consistent with data 
from miRNA tissue atlas that detected low miR30a-3p in normal pancreatic tissue 
(Ludwig et al. 2016). An interesting observation was that higher miR30a-3p expression 
in the tissue array was observed in the stage II of malignant pancreatic cancer, which is 
an important stage for the initiation of metastasis (Hidalgo 2010). Furthermore, 
malignant tissue displayed lower Cx43 expression compared to normal tissue, which 
underlines the significance of our previous findings on Cx43 expression in malignant 
pancreatic tissues (Forster et al. 2014). Similar results regarding the Cx43 expression in 
pancreatic cancer patients were found in the Human Protein Atlas Database, where 
immunohistochemistry data showed low or medium expression in most patients 
(https://www.proteinatlas.org/ENSG00000152661GJA1/pathology/pancreatic+cancer#
Location). The correlation of miR30a-3p and Cx43 expression was statistically 
significant, however it was poor, based on the Pearson correlation coefficient (r= - 
0.2911, a strong correlation is considered when r ≤ - 0.8) (Akoglu 2018). Likewise, Cx43 
expression was poor but significantly correlated with pathological staging of pancreatic 
cancer (r= - 0.3004). Possible reason for the poor correlation could be the variance in 
gene expression between ductal adenocarcinomas and different types of pancreatic 
cancer, that were examined within the tissue array, as well as the small patient cohort. 
Taken together, in this study I demonstrated that miR30a-3p and Cx43 in PDA tissues 
followed the expression pattern of my in vitro bioinformatic analyses. The correlation of 
Cx43 with miR30a-3p expression and malignancy of PDA were, to best of my 
knowledge, demonstrated for the first time.  
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8.2 Sulforaphane derivatives are proposed as new therapeutic agents 
for PDA 
There are many promising pre-clinical and clinical studies using sulforaphane as an anti-
cancer agent, however, a sulforaphane-based drug is not clinically approved until now. 
In the second part of my thesis, I examined whether a series of unprecedented derivatives 
of sulforaphane could exhibit better anti-cancer properties compared to the parental 
sulforaphane. Viability assay led to identification of two promising sulforaphane 
derivatives, SF102 and SF134. These two derivatives, and more effectively sulforaphane 
SF102, reduced viability and stem cell features of PDA cells by induction of apoptosis. 
Treatment with SF102 and SF134 also inhibited the xenograft tumor growth in vivo 
without inducing additional toxicity in chicken embryos and C.elegans. By conducting 
microarray analysis and bioinformatics evaluation, I detected similarities and differences 
in signal transduction among the treatments. The most striking similarity was that all of 
them had in common the regulation of NF-κB-related target genes. 
 
8.2.1 SF102 and SF134 induce cytotoxicity in cancer cells  
The establishment of sulforaphane analogues by molecular single atom changes in form 
of oxygen-to-nitrogen substitutions at the central sulfur atom, are unprecedented in the 
context of sulforaphane chemistry. SF102 and SF134 were the two out of the seven 
derivatives that could inhibit the viability, via induction of apoptosis, and the colony-
forming potential of PDA cells. To the best of my knowledge, this is the first time that 
the cytotoxicity of synthetic sulforaphane derivatives has been tested and evaluated in 
PDA cells. Previously, other synthesized sulforaphane derivatives were shown to inhibit 
proliferation of melanoma cells (Kielbasinski et al. 2014) or to induce cell cycle arrest 
and apoptosis in hepatocellular carcinoma cells (Hu et al. 2013). Shi et al. demonstrated 
that sulforaphane heterocyclic derivatives enhanced apoptosis and eliminated the CSC 
population in breast cancer cells (Shi et al. 2016).  
 
These data are in line with my results, as the most effective derivatives, SF102 and 
SF134, did not only inhibit the viability of PDA cells but also of breast, hepatocellular 




8.2.2 SF102 and SF134 did not cause significant side effects 
To confirm whether administration of sulforaphane derivatives could be effective in 
vivo, I used the fertilized chicken egg model. These experiments showed that SF102 
decreased tumor growth, inhibited proliferation and induced apoptosis by increasing the 
expression of caspase-3 at a higher rate compared to sulforaphane and SF134. 
Sulforaphane was previously shown to have no pronounced side effects in non-
malignant cells or in mice experiments (Kallifatidis et al. 2011), (Herr et al. 2013). 
Likewise, SF102 and SF134 caused no severe side effects in chicken embryos, as there 
were no signs of necrosis in the liver of the embryos or abnormal weight loss. To 
strengthen this observation, experiments on another animal model, C. elegans, 
demonstrated that sulforaphane derivatives did not disturb the lifespan and reproduction 
of the worms. Interestingly, SF102 even significantly induced longevity in the worms, a 
process that has been already proven to be anticarcinogenic (Kyriakakis et al. 2015). 
 
8.2.3 Similarities and differences of SF102 and SF134 regarding microRNA 
signaling and target gene induction 
My results suggest that SF102 and SF134 decrease the viability, clonogenicity, and 
tumor growth, and induce apoptosis in pancreatic cancer cells as potent or, in the case of 
SF102, even better than sulforaphane. Sulforaphane exhibits its anti-cancer activity in 
PDA mainly by normalizing the overactivated NF-B signaling in tumor stem cells and 
thereby mediates chemosensitization (Kallifatidis et al. 2009), (Appari et al. 2014). The 
bioinformatic analysis of miRNA data predict that sulforaphane, SF102 and SF134 affect 
NF-κB signaling by the induction of miR2278, which is involved in the regulation of 
many NF-κB target genes. Additionally, while sulforaphane inhibits the expression of 
miR27b-5p and miR29b-1-5p compared to untreated control cells, SF102 and SF134 
rather induce these miRNAs compared to their expression in sulforaphane-treated cells. 
This finding is of high relevance, because, according to our in silico analysis miR27b-
5p and miR29b-1-5p are also regulators NF-κB-related target genes. According to the 
Human Protein Atlas Database, the predicted target genes PLCG1 
(https://www.proteinatlas.org/ENSG00000124181PLCG1/pathology) and TRIM25 
(https://www.proteinatlas.org/ENSG00000121060-TRIM25/pathology) are of high 
relevance in pancreatic cancer, because patients with high PLCG1 (n = 110) or TRIM25 
(n = 121) expression survive longer than those with low expression (n = 66, n = 55, 
 
 78 
respectively). Interestingly, the miRNA candidates miR2278, miR27b-5p and miR29b-
1-5p have never before been documented in pancreatic cancer, as far as I know. The only 
available information about miR2278 and cancer is that its upregulation is associated 
with the inhibition of leukemic cell proliferation and enhanced apoptosis (Kaymaz et al. 
2015). However, Kim et al. demonstrated both miR27b-5p and miR29b-1-5p as markers 
for gastric cancer progression (Kim et al. 2018), while miR29b-1-5p overexpression 
induced epithelial-mesenchymal transition (EMT) in oral squamous cell carcinoma 
(Kurihara-Shimomura et al. 2019). 
 
Except of these three miRNAs and their regulation of the NF-κB target genes, another 
interesting question that arises is whether sulforaphane derivatives could have similar or 
better effect on the miR30a-3p/Cx43 mechanism that was mentioned in the first part of 
my study. Analysis of the miRNA data revealed that there was no difference in 
expression of miR30a-3p after SF102 or SF134 treatment compared to the control.  
Moreover, preliminary Western Blot results showed no influence on Cx43 expression 
after SF102 or SF134 treatment. The fact that sulforaphane derivatives could not 
reproduce the same result on miR30a-3p/Cx43 mechanism point outs that the original 
sulforaphane and its synthesized derivatives may differ in the mechanisms they induce 
to tackle PDA progression.  
 
8.2.4 Clinical relevance of sulforaphane derivatives synthesis 
During the last years, several clinical studies have been conducted with sulforaphane as 
a drug for cancer treatment. The most common method for delivery of sulforaphane to 
the patients is by sulforaphane rich-broccoli sprout extracts (Alumkal et al. 2015), 
(Lozanovski et al. 2019), because broccoli sprouts are known to contain a much higher 
amount of glucoraphanin, precursor of sulforaphane, compared to mature broccoli 
(Fahey et al. 1997). However, the daily intake of a large number of capsules in order to 
reach a high concentration of sulforaphane is very unpleasant for the patients and it can 
lead to high drop-out rates, as it occurred in the pilot study in the surgery department in 
Heidelberg (Lozanovski et al. 2019). Moreover, patients with terminal stage PDA 
anyway experience severe side effects from the disease and the high drug intake can lead 




Therefore, the development of a drug with highly active sulforaphane or a derivative 
thereof is urgently required to circumvent the unpleasant side effects of broccoli sprouts 
consumption and increase the intake of a high amount of sulforaphane within a single 
capsule. 
8.3 Conclusion 
My study proposes new sulforaphane-based therapeutic approaches in order to inhibit 
the progression of the highly aggressive PDA. 
 
Firstly, I demonstrated that sulforaphane enhances gemcitabine cytotoxicity in vitro and 
in vivo as a result of an increased bystander effect, mediated by inhibition of miR30a-3p 
and upregulation of GJ-related Cx43 expression. MiR30a-3p and Cx43 expression 
profile in PDA patients provided promising preliminary data for their significance in 
PDA progression. Future clinical studies are necessary to address whether a systemic 
application of sulforaphane or miR-30a-3p inhibitors can improve the efficacy of 
gemcitabine treatment in pancreatic cancer patients.  
 
Secondly, two derivatives of sulforaphane, SF102 and SF134, have been evaluated as 
new therapeutic agents. These two derivatives and especially SF102 showed strong 
inhibition in viability and colony formation in PDA cells and reduced the xenograft 
growth in vivo without profound adverse side effects. Therefore, sulforaphane 
derivatives can be a basis for the development of new therapeutic drugs with better 
pharmacokinetic properties in pancreatic cancer patients. However, more extensive 








PDA is one of the deadliest cancers with poor prognosis and profound therapy resistance, 
which is associated with the loss of gap junctional intercellular communication and Cx43 
expression. A promising bioactive agent with multiple anti-cancer activities is 
sulforaphane, an isothiocyanate that is naturally found in cruciferous vegetables. 
Sulforaphane restored the gap junctional intercellular communication and thereby 
therapy sensitivity in PDA and I investigated whether microRNA signaling is involved 
in this mechanism. Established cell lines were evaluated in vitro by gap junction and 
gemcitabine bystander effect assays, microRNA and gene arrays, bioinformatics 
analysis and luciferase reporter assay, while in ovo xenograft studies with miRNA-
transfected tumors were performed. miRNA and gene expression were also analyzed in 
patient tissue by in situ hybridization and immunohistochemistry. My results revealed 
that sulforaphane inhibited the expression of the top candidate miR30a-3p. Transfection 
with miR30a-3p inhibitors increased the gap junctional intercellular communication, 
Cx43 expression and gemcitabine bystander effect. In ovo, the xenotransplantation of 
these transfected cells decreased the tumor volume and enhanced the efficacy of 
gemcitabine. In a pancreatic cancer tissue array, the expression of miR30a-3p was 
present in malignant tissues but not in normal and the opposite result was observed for 
Cx43 expression. These findings provide new knowledge on the mechanism of 
sulforaphane-induced gap junctional intercellular communication and gemcitabine 
cytotoxicity in pancreatic cancer. With the aim to develop sulforaphane-based drugs for 
pancreatic cancer, I screened 7 unprecedented sulforaphane derivatives for their 
bioactivity against PDA and other tumor entities. MTT and colony forming assays, 
apoptosis analysis with flow cytometry, immunohistochemistry, microRNA studies as 
well as tumor xenograft and C. elegans studies were performed with these analogs. My 
observations suggest the anti-tumor activity of two out of the 7 derivatives, SF102 and 
SF134. SF102 was most effective in inhibition of viability, clonogenicity and tumor 
growth along with induction of apoptosis, followed by SF134, most importantly without 
obvious side effects. miRNA array profiling revealed differentially expressed candidates 
between sulforaphane derivatives and parental sulforaphane. My results indicate that 
sulforaphane-induced downregulation of the miR30a-3p enhances gap junctional 
intercellular communication and gemcitabine efficacy in pancreatic cancer. 






pancreatic cancer. I expect that the development of new sulforaphane- or sulforaphane 








Bauchspeicheldrüsenkrebs ist einer der tödlichsten Krebsarten mit schlechter Prognose 
und tiefgreifender Therapieresistenz, der mit dem Verlust der interzellulären 
Kommunikation und Cx43 Expression verbunden ist. Ein vielversprechender 
Pflanzenstoff mit mehreren anti-Krebs-Aktivitäten ist Sulforaphan, ein Isothiocyanat, 
das in Kreuzblütlern enthalten ist. Sulforaphan stellte die Gap Junction-Kommunikation 
und damit die Therapieempfindlichkeit der Chemotherapie bei 
Bauchspeicheldrüsenkrebs wieder her. Ich habe untersucht ob microRNAs an diesem 
Mechanismus beteiligt sind. Etablierte Zelllinien wurden in vitro durch Gap Junction 
und Gemcitabin Bystander Effekt assays, microRNA – und Gen arrays, 
Bioinformatische Auswertung getestet, während in ovo Xenograft Studien mit miRNA-
transfizierten Tumoren durgeführt wurden. MiRNA und Genexpression wurden auch in 
Bauchspeicheldrüsenkrebsgeweben durch in situ Hybridizierung und 
Immunhistochemie analysiert. Meine Ergebnisse haben gezeigt, dass Sulforaphan die 
Expression des Spitzenkandidaten miR30a-3p hemmt. Transfektion mit miR30a-3p 
Inhibitoren hat die Gap Junction-Kommunikation, Cx43 Expression und Gemcitabin 
Bystander Effekt verbessert. In vivo, die Xenotransplantation dieser transfizierten Zellen 
verringerte das Tumorvolumen und erhöhte die Wirksamkeit von Gemcitabin. In einem 
Bauchspeicheldrüsenkrebs-Gewebearray, war die Expression von miR30a-3p im 
Vergleich zu normalen Bauchspeicheldrüsen-Geweben erhöht und das umgekehrte 
Ergebnis wurde für die Cx43-Expression beobachtet. Diese Ergebnisse enthüllen den 
Mechanismus der Sulforaphan-induzierten Gap Junction-Kommunikation und der 
Gemcitabin-Zytotoxizität in Bauchspeicheldrüsenkrebs. Mit dem Ziel Sulforaphan-
bezogene Medikamente für den Bauchspeicheldrüsenkrebs zu entwickeln, habe ich 7 
einzigartige Sulforaphan-Derivate auf ihre Bioaktivität gegen den 
Bauchspeicheldrüsenkrebs und andere Tumorentitäten untersucht. MTT- und 
koloniebildende Assays, Apoptose Analyse mit Durchflusszytometrie, 
Immunhistochemie, MikroRNA-Array sowie Tumor Xenograft- und C.elegans Studien 
wurden mit diesen Analoga durchgeführt. Meine Ergebnisse deuten auf die Anti-Tumor-
Aktivität von zwei der SF Derivate, SF102 und SF134, hin. SF102 war am effektivsten 
bei der Hemmung der Lebensfähigkeit, Klonogenität und des Tumorwachstums 
zusammen mit der Induktion der Apoptose, gefolgt von SF134, vor allem ohne 






exprimierte Kandidaten zwischen Sulforaphan-Derivaten und ursprüngliches 
Sulforaphan. Meine Ergebnisse deuten darauf hin, dass die Sulforaphan-induzierte 
downregulation des miR30a-3p die Gap Junction-Kommunikation und die Gemcitabin-
Wirksamkeit bei Bauchspeicheldrüsenkrebs verbessert.  Sulforaphan-Derivate SF102 
und SF134 unterdrücken nachweislich das Fortschreiten von Bauchspeicheldrüsenkrebs. 
Ich vermute, dass die Entwicklung neuer Sulforaphan- oder Sulforaphan-Analoga –
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Figure S1. Bystander effect, flow cytometry plots for PDA cells. BxGEM and PANC-1 cells were 
treated as described in the methods paragraph and were co-incubated with the CTR-untreated cells. After 
48h, the cells were stained with 7-AAD and then evaluated for cell death by flow cytometry. The 
percentage of double-positive cells (CTR+/7-AAD+) is an indicator of the bystander effect. The 










Figure S2: Sulforaphane-regulated gap junction pathway map. A map of the gap junction pathway 
from the KEGG pathway database, demonstrating the expression profile of GJA1 and other GJ genes. The 
































Figure S3. Description of the pancreas tissue array. For each patient tissue section, the TNM, clinical 







































Transcript ID(Array Design) Estimate of BxG SF vs BxG CO -log10(p-Value) for Estimate of BxG SF vs BxG CO 
hsa-miR-30a-3p -0,515691759 2,307500498 
hsa-miR-103a-3p 0,282360185 2,099375036 
hsa-miR-192-5p 0,243035685 2,651196084 
hsa-miR-196a-5p -1,719896056 4,54498928 
hsa-miR-10a-5p -0,683088296 3,418595976 
hsa-miR-205-3p -1,302094185 2,372354101 
hsa-miR-181a-3p -1,814912926 2,789621402 
hsa-miR-210-3p -0,77576313 2,220046044 
hsa-miR-221-3p -0,247226296 2,317880426 
hsa-miR-23b-5p -1,223345481 3,364836848 
hsa-miR-27b-5p -1,481377278 6,677552014 
hsa-miR-27b-3p -0,655353333 3,723717471 
hsa-miR-125b-5p -0,352389259 2,79827584 
hsa-miR-132-5p -0,739552556 2,335439443 
hsa-miR-135a-3p 1,50770742 3,433865762 
hsa-miR-194-5p 0,21495963 3,884431449 
hsa-miR-365a-3p -0,778674946 2,370976267 
hsa-miR-365b-3p -0,779343781 2,369460275 
hsa-miR-151a-5p -0,136245556 2,313935953 
hsa-miR-335-5p -1,798210204 2,243135485 
hsa-miR-431-5p -0,432510994 2,867277056 
hsa-miR-486-5p -0,568198537 2,992447158 
hsa-miR-486-3p -1,021382648 2,450515817 
hsa-miR-193b-5p 1,060048981 3,243830342 
hsa-miR-499a-3p -0,522496961 2,523593988 
hsa-miR-508-5p 0,522536409 2,911859612 
hsa-miR-568 -0,451092843 2,90932264 
hsa-miR-574-5p -0,974587463 2,799837442 
hsa-miR-550a-5p 0,521688204 2,334550241 
hsa-miR-605-3p -0,427579811 3,111549879 
hsa-miR-663a 0,547952 2,468853453 
hsa-miR-1301-3p 0,942618352 2,482661487 
hsa-miR-378d -1,265947296 3,091790789 
hsa-miR-675-5p -1,639689111 4,213668454 
hsa-miR-298 -0,840100639 3,036088093 
hsa-miR-1469 0,618989611 3,272190322 





Table S2. List of miRNA candidates shown in the heatmaps of Figure 27B. 
 
Transcript ID(Array Design) Fold change As SF vs As CO -log10(p-Value) for Fold change As SF vs As CO 
hsa-miR-92a-1-5p -1,372521778 3,75505874 
hsa-miR-139-5p 1,643831167 2,171386888 
hsa-miR-181a-3p -1,517916889 2,264995123 
hsa-miR-23b-5p -1,320086537 3,641174453 
hsa-miR-27b-5p -1,481057778 6,676530399 
hsa-miR-200a-5p -1,008850574 4,535356109 
hsa-miR-933 1,004593711 2,82838023 
hsa-miR-2278 -1,454670037 4,497590006 
hsa-miR-3617-5p 1,375816648 4,164613745 
hsa-miR-29b-1-5p -0,836535981 5,822817777 
   
Transcript ID(Array Design) Fold change As 102 vs As CO -log10(p-Value) for Fold change As 102 vs As CO 
hsa-miR-222-5p -1,619505926 2,46987786 
hsa-miR-608 -0,813965009 2,51964538 
hsa-miR-885-3p -1,1512765 2,14622962 
hsa-miR-2278 -1,953776504 5,779851604 
hsa-mir-3130-1 0,544790541 2,550401342 
hsa-miR-514b-5p 0,961224581 2,110771925 
hsa-miR-4784 -0,617792344 4,283023847 
hsa-miR-4701-3p -1,645821574 2,327247792 
hsa-miR-4740-5p 1,454254422 2,273906768 
hsa-miR-6823-3p 0,841931665 2,209963967 
   
Transcript ID(Array Design) Fold change As 134 vs As CO -log10(p-Value) for Fold change As 134 vs As CO 
hsa-miR-509-5p 0,990048778 3,475932331 
hsa-miR-550b-2-5p 0,984038667 3,368279238 
hsa-miR-885-3p -1,132580519 2,103883581 
hsa-miR-2278 -1,576873574 4,835629473 
hsa-miR-4444 1,660302852 2,810881792 
hsa-miR-4517 1,279263833 2,004627051 
hsa-miR-4640-5p -1,574678796 2,376120891 
hsa-miR-4776-5p 1,217612185 2,226594385 
hsa-miR-6729-3p 1,002040461 2,669521405 





Table S3. List of the differently expressed miRNAs for Venn diagram of Figure 27D. 
 
 










Table S4. Bioinformatics analysis of target genes of the identified miRNA candidates miR2278, 
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